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Abstract
Staphylococcus aureus is a component of normal flora colonizing skin and nares, but it is also
one of the most common causes of serious infections, especially sepsis. The dysfunctional
immune response during sepsis often leads to tissue damage and organ failure, including acute
lung injury. Among the virulence factors that likely drive the high morbidity and mortality
associated with S. aureus sepsis and tissue injury are enterotoxins, including S. aureus
enterotoxin A (SEA). SEA directly crosslinks MHC II molecules and specific Vβ chains of T cell
receptors resulting in oligoclonal activation of T cells and massive immune response. Previous
studies showed that SEA inhalation in mice caused a rapid activation of SEA-specific T cells
and cytokine release into circulation. This systemic inflammatory response was followed by
SEA-specific T cell expansion in lymphoid tissues and lung, which was accompanied by
development of pulmonary pathology and increased vascular permeability. The aims of this
study were to (1) define the crosstalk between adaptive immunity and innate immune cells
during the systemic inflammatory response, (2) further characterize SEA-induced pulmonary
inflammation and understand the mechanism leading to increased permeability in lung, and (3)
determine the role of alveolar macrophages in the systemic inflammatory response due to SEA
inhalation. The results demonstrated that after inhalation, SEA disseminated systemically via
blood and triggered rapid transcriptional changes in T cells followed by a systemic recruitment
of neutrophils and monocytes into circulation and lymphoid tissues. TNF and CD28 signaling
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played unique but also overlapping roles in the migration of innate immune cells. Furthermore,
this study shows that the injury to the pulmonary endothelial cells was dependent both on early
immune responses due to T cell activation as well as on later inflammatory processes through
CD54 engagement. Finally, alveolar macrophages were shown to play a critical role in binding
SEA within the lung mucosa and their ablation was associated with increased T cell activation
and cytokine release. Altogether, these findings demonstrated the elaborate pathways involved
in SEA-evoked inflammation. Understanding the mechanisms of S. aureus enterotoxin-induced
systemic and pulmonary response may unravel novel therapeutic options for S. aureus
infections.
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Chapter 1: Introduction

General comments
Acute inflammation is a rapid and vital reaction to injury, trauma or infection. The goal of
acute inflammatory response is to activate local cells (e.g. tissue macrophages or endothelium),
recruit leukocytes and induce a milieu of pro- and anti-inflammatory mediators, which eventually
leads to resolution of inflammation, healing and tissue regeneration. In certain instances,
however, it may also result in further propagation of the inflammatory response and organ
dysfunction (1). Typical examples of excessive inflammatory response causing tissue damage
include systemic inflammatory response syndrome (SIRS) and the related sepsis as well as
acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). Understanding how acute
inflammation is contained, how it subsides and how it becomes uncontrolled and exaggerated is
crucial for the development of better therapeutic strategies.
A key cellular component of acute inflammatory response is the innate immune system,
particularly, neutrophils, monocytes, and macrophages. These cells can be quickly activated
and recruited to the site of injury. Furthermore, they can mount relatively nonspecific defense
mechanisms against various inflammatory, nocuous, or alarm signals. These mechanisms
include phagocytosis and release of reactive oxygen species, cytokines, chemokines, lytic
enzymes and other mediators (2-4). Because of their ability to elicit a rapid and robust
nonspecific immune response, innate immune cells are thought to be the mediators of tissue
damage in cases of overly activated immune response, i.e. in SIRS/sepsis or ALI/ARDS. Thus,
innate immune responses and particularly neutrophils have been targeted in many studies in
order to develop novel treatments for these life-threatening conditions (5, 6). Unfortunately,
there is currently no approved pharmacotherapy for the treatment of SIRS/sepsis and ALI/ARDS
(7, 8). A part of the issue is undoubtedly the fact that these conditions have an overly complex
etiology and pathophysiology, and they involve a plethora of villainous mediators. Thus,
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targeting a single agent may not be sufficient to achieve therapeutic success in all patients.
However, it is also likely that an important part of the immune response has been neglected
over the years in the study of injurious, excessive inflammation: the adaptive immunity and
particularly T cells.
Adaptive immune response is usually considered delayed compared to the innate
immunity. Nevertheless, it can also induce a rapid and over-exuberant inflammation when
stimulated with specific agents. This is particularly relevant in the case of superantigens.
Superantigens, such as S. aureus enterotoxins, are known for their ability to trigger oligoclonal
activation of T cells and a cytokine storm. This rapid T-cell mediated inflammatory response can
cause serious organ injury and even death (9, 10). This work explores the mechanisms of S.
aureus enterotoxin-induced inflammation and uncovers potential therapeutic targets. The first
chapter introduces the topics of S. aureus enterotoxins, SIRS and ALI. The second chapter
contains materials and methods used in the experimental studies. Chapter 3 investigates
systemic inflammatory response in the context of S. aureus enterotoxin. Chapter 4 focuses on
the mechanisms of pulmonary inflammation due to S. aureus enterotoxin. Chapter 5 explores
the role of alveolar macrophages in S. aureus enterotoxin-induced inflammation. Finally, chapter
6 offers concluding remarks and future directions.

Staphylococcus aureus and superantigens
Staphylococcus aureus is a Gram-positive, facultative aerobe that colonizes anterior
nares, pharynx, or skin in asymptomatic individuals. In fact, 20% (range 12-30%) of the general
population has a persistent nasal carriage of S. aureus and 30% (range 16-70%) are
intermittent carriers (11). However, in addition to being a commensal organism, S. aureus is
also recognized as one of most significant causes of life-threatening infectious diseases in the
United States (9, 12). In particular, the methicillin-resistant form of S. aureus (MRSA) poses a
major threat in hospital settings (12, 13) and although the incidence of MRSA in the United
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States has been declining likely due to better prevention strategies, it is currently estimated to
cause over 80,000 cases of invasive infections annually (14). Because of its versatile virulence
factors, S. aureus can evade the immune defenses of the host and cause a variety of infections:
including benign soft tissue abscesses as well as life-threatening infections such as bacteremia
and sepsis, pneumonia, endocarditis or osteomyelitis (12, 15). Among the wide array of
secreted or surface-bound virulence factors is a group of toxins known as superantigens.
Superantigens, such as S. aureus enterotoxins, are nonglycosylated low-molecularweight exotoxins (9). There are about 40 different bacterial superantigens that are typically
produced by S. aureus or Streptococci species (10). Staphylococcal superatigens are usually
encoded by accessory genetic elements, such as prophages, plasmids, transposons, or
pathogenicity islands and thus, they are not uniformly present in all clinical isolates (10).
Nevertheless, it has been reported that the majority of strains carry at least one superantigen
gene (9, 16-18). The regulation of superantigen synthesis by the bacteria is currently not well
understood but at least in the case of S. aureus enterotoxins it appears to be induced during or
at the end of the exponential growth phase (19, 20).
Superantigens have a unique ability to bypass antigen processing and directly bind to
the major histocompatibility complex class II (MHC II) of antigen presenting cells (APCs). In fact,
even metabolically inactivated APCs are still capable of presenting a superantigen (21, 22). The
binding of superantigens to MHC II is extremely stable and can generally occur through the α
chain and in some cases also the β chain of MHC II (10). After directly binding to MHC II,
superantigens can then crosslink it with specific Vβ chains of T cell receptors (TCRs). The
engagement of Vβ chains is determined by the shallow cavity at the top of the protein (10, 23).
Superantigens are also much more promiscuous compared to other antigens. Each
superantigen can bind to several different Vβ regions; for example, in mice, S. aureus
enterotoxin A (SEA) can bind to Vβ1, 3, 10, 11 and 17. Furthermore, whereas conventional
antigens are restricted by MHC I and MHC II binding, superantigens can activate both CD4+ and
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CD8+ T cells with a specific TCR Vβ chain (23). Thus, compared to conventional antigens which
usually activate 1/104-106 T cells, superantigens can stimulate up to 1/4 T cells (22). This rapid
activation of a large number of T cells causes a cytokine storm and the elevated levels of IL-2,
TNF and IFNγ in the bloodstream are generally believed to be the main cause of toxicity (10).
Furthermore, as the term “enterotoxin” indicates, some S. aureus enterotoxins possess
a strong emetic activity and in fact, ingestion of superantigens is a major cause of food
poisoning (24). The mechanism of emesis induction is not completely understood. However, the
presence of a cystine loop seems be required for emetic activity while it appears to be
independent of MHC II and TCR binding (9, 24), In addition to their ability to induce systemic or
enteric toxicity, most superantigens are remarkably stable: they are resistant to heat, boiling,
acids, proteolysis and dessication. Thus, their biological toxicity and environmental stability
makes them extremely dangerous agents and some are currently categorized as potential
weapons of bioterrorism (9).
Although all superantigens share their ability to stimulate a large number of T cells, they
exhibit different binding properties to MHC II as well as different emetic activity depending on
the presence of the cystine loop. These structural features can be used to separate
superantigens into 5 groups. Table 1.1 represents categorization of staphylococcal
superantigens (adapted from Spaulding et al. (9)). The ability to engage not only the α chain but
also the β chain of MHC II appears to play a critical role in the overall potency. In particular, the
second binding site to the β chain of MHC II also known as Zn2+-dependent MHC II binding site
increases the persistence of a superantigen on cell surface and may allow for crosslinking of
adjacent APCs (25, 26). Thus, superantigens that bind both the α and the β chains of MHC II
have about 10- to 100-fold greater toxicity compared to superantigens binding only to the α
chain (9). Finally, recent studies identified two other important engagement sites for
superantigens, the costimulatory receptor CD28 on T cells and its ligand CD86 on APCs (27,
28). Direct binding of a superantigen to these sites enhances the CD28/CD86 costimulation
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axis and it appears to play a crucial role in the extent of T cell activation, cytokine storm and
overall lethality due to a superantigen exposure (27-29).

Immune response to superantigens
The ability of superantigens like S. aureus enterotoxins to directly bind to MHC II
molecules and bridge them with specific Vβ chains of TCRs triggers a potent immune response.
First, the high affinity of superantigens for MHC II induces a rapid activation of T cells. In fact, as
early as 1 h after SEA inhalation, the early T cell activation antigen CD69 was upregulated on
about 80% of SEA-specific T cells in mediastinal lymph nodes (LNs) and by 5 h, about 80% of
SEA-specific T cells were positive for both CD69 and IL-2 receptor, CD25 (30). Upon activation,
T cells and APCs respond by releasing a number of different cytokines and chemokines. In
particular, the production of IL-2, TNF, and IFNγ by T cells is a pronounced feature of a
superantigen exposure (31-33). Together with other cytokines and chemokines, such as IL-6,
IL-12, or CCL2 (34, 35), this so-called cytokine storm is thought to mediate the serious
symptoms of toxic shock (10, 36).
Superantigens and particularly S. aureus enterotoxins were initially described as potent
T cell mitogens (37, 38). Following activation, superantigen-specific T cell populations undergo
5-6 rounds of division, resulting in a significant accumulation of T cells (23, 34, 39, 40). For
instance, in a model of SEA inhalation in mice, Vβ3+ SEA-specific T cells underwent a massive
expansion in all lymphoid tissues as well as the lung by 2 days after exposure. Apart from the
actual numbers, the percentage of Vβ3+ T cells in the spleen increased from about 3% to 30% of
the total T cell population (39). In addition, superantigen-stimulated T cells exhibit effector and
cytotoxic phenotype. In particular, 2 or 3 days following S. aureus enterotoxin exposure, CD8+ T
cells were shown to express high levels of IFNγ, granzyme B, and perforin (30, 39, 41) and their
accumulation in lung was associated with increased cell number and protein concentration in
the bronchoalveolar lavage (BAL) fluid, indicating tissue injury (39).
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Following expansion, superantigen-specific T cells undergo clonal deletion or
programmed death (42-45). The activation-induced cell death (AICD) due to S. aureus
enterotoxin was found to only occur in proliferating T cells and the apoptotic cells upregulated
CD95 (Fas) as well as CD178 (FasL) (46, 47). Interestingly, AICD could be prevented when
mice were simultaneously exposed to bacterial lipopolysaccharide (LPS). The survival of T cells
was dependent on TNF and to a lesser extent IFNγ and the rescued T cells were unresponsive
to Fas engagement (48).
Not all specific T cells become deleted and these cells display an anergic phenotype
(49-51), defined as inability to proliferate or produce cytokines upon restimulation (52). There
are two proposed mechanisms of superantigen-induced T cell anergy: intrinsic and extrinsic. An
intrinsic deficit is characterized as inert change in cell signaling or transcriptional activity.
Several studies reported molecular changes in TCR signaling of anergic cells, particularly
defective protein phosphorylation and altered function of transcriptional factor AP-1 (53, 54).
The presence of an intrinsic anergic state was also shown using in vivo transfer experiments
where anergic T cells transferred to a naïve recipient failed to proliferate upon S. aureus
enterotoxin restimulation while naïve T cells transferred into an anergic recipient proliferated
(55). In contrast, an extrinsic deficit would be attributed to an outside suppressor, such as
cytokine or cell-to-cell contact. In particular, mechanistically, it was shown that anergy of CD4+ T
cells was dependent on the presence of myeloid cells, NO synthase activity, reactive oxygen
species, and IFNγ (52, 56). An important source of IFNγ are CD8+ T cells (39); indeed, CD4+ T
cell anergy was enforced by CD8+ T cells (57). Furthermore, the unresponsiveness of
superantigens could be attributed to immunosuppression due to augmentation of Treg
population (58-60). Recently, it was also proposed that superantigen interaction with APCs not
only induces pro-inflammatory responses but also plays a role in inducing unresponsiveness
through increased expression of IL-10, programmed death ligand-1 (PD-L1), also
immunosuppressive molecule indoleamine 2,3-dioxygenase - IDO (61).
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Finally, it is important to note that there are some differences between human and
mouse responses to superantigens. Human T cells are exquisitely sensitive to superantigens. In
some cases, human T cells cultured in vitro can respond to 1 fg/mL of superantigen (10).
Furthermore, it has been estimated that an amount of 0.0013 µg/kg of body weight could be life
threatening to a human. In contrast, mice are quite resistant to superantigens and unless they
are genetically modified or pre-treated with sensitizing agents, such as D-galactosamine, they
do not generally develop symptoms of toxic shock or succumb to superantigens (62).
Nevertheless, similarly to humans, murine immune system responds to superantigens by
oligoclonal activation and expansion of T cells, cytokine release, as well as the subsequent T
cell anergy (31-33, 40, 44, 63, 64). Thus, studying these responses can lead to a better
understanding of the pathology and eventually to a development of novel treatments.

Role of superantigens in systemic and pulmonary diseases
Superantigens were initially associated with a condition known as toxic shock syndrome
during its outbreak in children in the late 1970s (65). Since then, the involvement of
superantigens in the pathology of various human diseases has been a focus of many studies.
Some of the recognized illnesses linked to superantigens include food poisoning, atopic
dermatitis, and allergic rhinitis (10). Recent evidence has also demonstrated a causal
relationship between staphylococcal superantigens and S. aureus pneumonia and sepsis (9).
These conditions are discussed below in greater detail.

Toxic shock syndrome
Toxic shock syndrome is a systemic response to superantigen exposure, particularly
toxic shock syndrome toxin-1 (TSST-1) and S. aureus enterotoxins. By 1980, several studies
reported development of toxic shock in young menstruating women, which was related to the
use of high absorbency tampons and the presence of TSST-1 (9, 66-68). In contrast, non-
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menstrual toxic shock syndrome may result from any primary S. aureus infection and can be
caused by TSST-1 as well as S. aureus enterotoxin A, B, or C (36, 69). In addition, while there
was no mortality in menstrual toxic shock syndrome, non-menstrual toxic shock syndrome
cases had a mortality of 22% (70). The classical symptoms of toxic shock syndrome resemble
influenza-like illness and include high fever, vomiting, diarrhea, headache, sore throat, myalgia,
and erythematous, desquamating rash (10, 36). Following the outbreak of menstrual toxic shock
syndrome in the 1980s, the incidence of the disease has been considered relatively low;
however, it is likely that a lack of a diagnostic test and the stringent definition of characteristic
symptoms lead to an underestimation of the actual rates (69).

Systemic inflammatory response syndrome and sepsis
SIRS and the related sepsis are devastating medical conditions with increasing
incidence worldwide and no available pharmacotherapy (7). SIRS is a broad term used to define
a group of systemic symptoms that occur as a physiologic response to a variety of acute insults,
such as infection, trauma, hemorrhage or immune-mediated organ injury (71) . A recent study
estimated that SIRS occurs in over 16 million adult patients in the emergency department within
the United States annually (71). The symptoms of SIRS include tachycardia (heart rate >90
beats/min), tachypnea (respiratory rate >20 breaths/min or partial pressure of carbon dioxide
PaCO2 <32 mmHg), fever or hypothermia (temperature >38.5°C or <35°C) and changes in white
blood cell count (WBC); either increase in WBC of more than 12,000 cells/mm3 or decrease in
WBC of less than 4000 cells/mm3 (7, 72). Sepsis is often defined as SIRS in the presence of a
known or suspected infection and is thought to affect more than 1,000,000 people in the United
States every year (7, 73). Although recent advances in critical care reduced the overall rate of
in-hospital deaths, the mortality due to sepsis remains unacceptably high with estimates
between 20-30%. Furthermore, the surviving patients remain at increased risk for death even
after recovery and may suffer from impaired physical and neurocognitive functioning (72).
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The general mechanism of SIRS/sepsis pathophysiology is shown in Fig. 1.1. Following
an inflammatory trigger, such as pneumonia, trauma or surgery, the immune system and
specifically innate cells - neutrophils, monocytes and macrophages - become activated (e.g.
through pattern recognition receptors) and trigger a robust inflammatory response, involving
cytokines, chemokines, the complement system as well as platelets. Similarly, the adaptive
immunity and particularly T cells can get stimulated upon interaction with APCs. Both pro- and
anti-inflammatory factors can be released simultaneously; therefore, patients may present with
either hyperinflammatory state (SIRS) or immunosuppressive state (compensatory antiinflammatory response syndrome or CARS). These changes may be accompanied by
coagulation abnormalities, which can manifest as disseminated intravascular coagulation (DIC)
as well as impaired neuroendocrine regulation that normally controls aspects of
immunosuppressive mechanisms. Together, these systemic responses can lead to increased
oxidative stress, tissue hypoperfusion, and loss of barrier function (72, 74, 75). Tissue injury
may lead to organ dysfunction and if several organs are involved (e.g. lung or kidney), it is
known as multiple organ dysfunction syndrome (7). Finally, if patients suffer from hypotension
refractory to fluid resuscitation, they are in septic shock, a serious condition with a high mortality
rate (72).
While initially the predominant causative organisms were Gram-negative bacteria, more
recent data demonstrated an increasing incidence of Gram-positive bacteria and fungi. In
particular, Gram-positive bacteria were found in 37.6% of cases (76). Even more recently, a
large epidemiologic study of serious infections in intensive care units found Gram-positive
bacteria in 47% of patients with S. aureus present in 20% (77). In Gram-negative bacteria, LPS
plays a dominant role in initiating the inflammatory cascade in sepsis. However, Gram-positive
bacteria do not have LPS and possess other virulence factors, such as superantigens (78). In
fact, superantigen-expressing S. aureus strains or superantigen proteins were found in septic
patients, and the prevalence of SEA correlated with the severity of the disease (79-81). SEA
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was also found in 25% of burn injury patients (population susceptible to serious infections and
sepsis) and its presence increased the likelihood of mortality by 11% (82). Furthermore, a
recent study demonstrated that neutralization of superantigen S. aureus enterotoxin K present
in the common MRSA strain USA300 increased survival in an intravenous challenge model in
mice (83). Similarly, neutralization of S. aureus enterotoxin B in a mouse model of MRSA
infection prevented lethal sepsis and reduced skin tissue invasion and abscess formation (84).
Finally, the presence of superantigen S. aureus enterotoxin C was critical in inducing tissue
injury and driving lethality in a rabbit model of S. aureus sepsis (85).

Pneumonia, acute lung injury and acute respiratory distress syndrome
ALI/ARDS affects 200,000 adults in the United States annually and has a mortality of
about 40% (86). Furthermore, a recent multinational epidemiologic study identified that over
10% of intensive care unit patients develop this devastating condition, suggesting that
ALI/ARDS is largely underdiagnosed (87). ALI is characterized by bilateral pulmonary infiltrates
with arterial hypoxemia due to accumulation of edema fluid and impaired gas exchange (the
concentration of arterial oxygen divided by the inspired fraction of oxygen PaO2/FiO2 <300). If
PaO2/FiO2 <200, the patient is diagnosed with ARDS (88). ALI/ARDS can be caused by direct
(pulmonary) and indirect (extrapulmonary) causes. Direct causes include pneumonia, aspiration,
pulmonary contusion, or toxic inhalation, whereas indirect causes include sepsis, extrathoracic
trauma, burn injury, drug overdose, or pancreatitis (89). However, pneumonia and sepsis
represent the most common triggers. The hallmark of ALI/ARDS pathology is increased
vascular permeability due to endothelial injury. This is accompanied by injury to the lung
epithelial cells, pulmonary edema, accumulation of red blood cells and immune cells in the lung
tissue, particularly neutrophils, macrophages, and monocytes (88). The mechanism of
ALI/ARDS is not fully understood; however, because of the significant neutrophil infiltration,
neutrophils are often considered to be a critical part of the pathogenesis (88).
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Despite a number of clinical trials, there is currently no pharmacotherapy for the
treatment of ALI/ARDS. These included clinical trials testing treatments focused on inhibition of
neutrophil and macrophage function, such as neutrophil elastase inhibitor or antioxidant Nacetylcysteine, and they showed no change in mortality (8). Thus, it is likely that other
mechanisms are in place that may drive the pathology in ALI/ARDS. In particular, the role of T
cells in the pathogenesis of ARDS is only now beginning to emerge (90). Previous studies
demonstrated that there were elevated numbers of lymphocytes in the blood and BAL fluid of
ALI/ARDS patients (91, 92). Furthermore, ALI/ARDS patients also showed an increase in a T
cell specific cytokine IL-2 in the BAL fluid and its levels were correlated with increased mortality
(93, 94). One potential explanation for the presence of T cells in ALI/ARDS is superantigens. In
fact, the involvement of superantigens in a number of airway diseases, such as allergic rhinitis,
nasal polyposis and asthma has been a focus of many studies (95). Moreover, recent reports
demonstrated that preimmunization against superantigens prevented fatal necrotizing
pneumonia in rabbits infected with a common USA200 MRSA strain (96, 97). Finally,
aerosolized S. aureus enterotoxin caused serious pulmonary inflammation and death in 3 out of
6 rhesus monkeys (98). Unfortunately, there is currently a lack of human studies that would link
superantigens to sepsis- or pneumonia-induced ALI/ARDS. Such studies will be necessary to
confirm the role of superantigens in ALI/ARDS.

The model of S. aureus enterotoxin inhalation in mice
S. aureus enterotoxins and other superantigens are known to induce robust systemic
responses, but how they spread systemically is not clear. One possibility is that they are directly
produced in blood during S. aureus bacteremia. However, several studies demonstrated that
hemoglobin peptides inhibit superantigen production by S. aureus (99, 100) and therefore, they
likely disseminate systemically from focal sites of infection rather than being synthesized in the
bloodstream by the bacteria (9). The anterior nares are known to be the most common
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colonization site of S. aureus, which can be attributed to the route of transmission: S. aureus is
commonly transferred from various surfaces by hands to the nasal niche via “nose picking” (11).
Nasal carriage of S. aureus and particularly MRSA was shown to increase the risk of acquiring
an infection with this pathogen 4-fold (101-103). Thus, inhalation of S. aureus enterotoxin may
closely resemble the route of dissemination in humans. In fact, several reports of accidental
exposure to aerosolized S. aureus enterotoxin in humans showed systemic symptoms of chills,
headache, fever, myalgia, cough, dyspnea, vomiting and diarrhea (104).
In mice, S. aureus enterotoxin inhalation initiates an inflammatory cascade through
systemic activation of specific T cells, accompanied by a robust cytokine release into circulation,
including, IL-6, TNF or IFNγ. In addition to the systemic changes, S. aureus enterotoxin-specific
αβ T cells in the lung induce IL-17 release by γδ T cells, which aids recruitment of neutrophils
into the airways. This early systemic inflammatory response occurs within several hours after
inhalation. By 48 h, S. aureus enterotoxin-specific T cells expand in all lymphoid tissues as well
as the lung. The increased protein concentration and cell number in the BAL fluid (particularly,
innate cells, NK cells and T cells) are indicative of pulmonary injury. Histologically, the lung
tissue showed perivascular and peribronchial inflammation, disruption of terminal vessels, and
accumulation of red blood cells, leukocytes and proteins (30, 34, 39, 105, 106). Although these
studies highlighted key features of S. aureus enterotoxin-induced inflammation, there are many
remaining questions. In particular, it is not known how S. aureus enterotoxin spreads
systemically following inhalation, what is the crosstalk between the adaptive immune system
and innate cells and how S. aureus enterotoxin drives lung injury and increased vascular
permeability. The following studies investigate the mechanisms of systemic and pulmonary
immune responses after SEA inhalation.
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FIGURE 1.1: Diagram of general processes involved in sepsis. Sepsis can be triggered by a
number of inflammatory stimuli, such as pneumonia, trauma, or surgery. The inflammatory
trigger induces an overwhelming immune response (e.g. through pattern recognition receptors),
particularly involving innate immune cells: neutrophils, monocytes and macrophages (MΦs).
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Recent evidence suggests that T cells (particularly through superantigen-induced activation)
may also play a critical role in the pathogenesis of sepsis. The activated immune cells release
pro-inflammatory factors, cytokines and chemokines, which further activate platelets and the
complement system. The resulting response triggers a state of hyperinflammation known as
systemic inflammatory response syndrome (SIRS), which may be counterbalanced by a state of
immunosuppression known as compensatory anti-inflammatory response syndrome (CARS). As
a consequence of the increased inflammation, tissue and vasculature become injured due to
oxidative stress, hypoperfusion, and disseminated intravascular coagulation (DIC). Multiple
organs can be affected, including lung or kidney (multi-organ dysfunction syndrome; MODS).
The vascular injury leads to hypotension, which if refractory to fluids is known as septic shock.

Group
I

Low affinity
binding to α chain
of MHC II

High affinity
binding to β chain
of MHC II

Presence
of cystine
loop

✔

✖

✖

Representative
superantigens
TSST-1, SE-l X
SEB, SEC, SEG, SE-l
U, SE-l W, SPE A,

II

✔

✖

✔

SSA
SEA, SED, SEE, SE-l
H, SE-l J, SE-l N to

III

✔

✔

✔

SE-l P
SPE C, SPE G, SPE

IV

✔

✔

✖

J, SMEZ
SE-l I, SE-l K to SE-l
M, SE-l Q to SE-l T,

V

✔

✔

✖

SE-l V, SPE H

TABLE 1.1: Categorization of superantigens. The table represents categorization of
staphylococcal and streptococcal superantigens based on their structural properties. TSST-1 =
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toxic shock syndrome toxin-1, SE = staphylococcal enterotoxin, SE-l = staphylococcal
enterotoxin-like protein, SPE = streptococcal pyrogenic exotoxin, SSA = streptococcal
superantigen, SMEZ = streptococcal mitogenic exotoxin Z. Adapted from Spaulding et al. (9).
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Chapter 2: Materials and Methods

Mice
C57BL/6J (WT), MHC II−/−, and TCR βδ−/− mice were obtained from Jackson Laboratory (Bar
Harbor, Maine). CD169-DTR mice were a kind gift from Dr. Kamal M. Khanna (UConn Health,
Department of Immunology, Farmington, CT). Mice were used between 1.5 and 4 months of
age. All mice were kept in the Central Animal Facility at UConn Health in accordance with
federal guidelines. All experimental procedures were approved by the Institutional Animal Care
and Use Committee of UConn Health.

Toxin administration
To administer SEA, mice were anesthetized with isoflurane (Phoenix, St. Joseph, MO) in a
vaporing chamber (Midmark, Versailles, OH). In most studies, 1 µg of SEA (Toxin Technology,
Sarasota, FL) diluted in 50 µL of balanced salt solution (BSS) or BSS alone (vehicle) was
pipetted on the nostrils (intranasal route – i.n.). In SEA titration experiments, 0.033 µg, 0.1 µg,
0.33 µg or 1 µg of SEA was administered i.n. as described before. The mice recovered from the
anesthesia immediately after inhaling the toxin or vehicle control.
To ablate CD169+ cells in CD169-diphteria toxin receptor (DTR) mice, mice received 40 ng/g of
body weight of diphtheria toxin (DT; Sigma-Aldrich) intraperitoneally (i.p.) 2 days before SEA or
vehicle inhalation. Flow cytometry of the lung tissue was used to confirm cell depletion 2 days
following DT injection.

Adoptive transfer
To adoptively transfer T cells, spleen and peripheral LNs (axillary, brachial, and inguinal) were
collected from naïve WT mice. The tissue was passed through 100-µm strainer (Falcon/BD
Biosciences) and RBCs were lysed with an ammonium chloride solution. The single cell
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suspension was washed, re-suspended in 3 mL of BSS and then pipetted onto a nylon wool
column. The column was then incubated at 37°C for 30 min. This step was repeated after
pushing 3 mL of BSS through the column. The column was then flushed with BSS and the
enriched cells were counted using Z1 particle counter (Beckman Coulter, Brea, CA). The purity
of the cells was determined by flow cytometry (FACS LSRII; BD Biosciences). After
anesthetizing mice with ketamine/xylazine solution (10 mg/mL of ketamine, 0.5 mg/mL of
xylazine in PBS injected i.p. as 10µL/g of body weight), enriched T cells (~3.5×106 T cells) were
adoptively transferred into TCR βδ-/- recipient mice by retro-orbital injection as previously
reported (30, 39).

In vivo antibody neutralization
For neutralization therapy experiments, mice received an i.p. injection of the following agents
diluted in PBS:
TABLE 2-1: Antibodies used in vivo.
Antibody

Clone

Dose

Isotype control

Source

used
Anti-4-1BBL

TKS-1

200 µg

Rat IgG2a

Anti-CD40L

MR1

500 µg

Hamster IgG

BioXCell, Lebanon,
NH
BioXCell

Anti-CD54

YN1/1.7.4

500 µg

Rat IgG

BioXCell

Anti-CD178

101626

250 µg

Rat IgG

Anti-TNF

XT3.11

500 µg

Rat IgG

R&D Systems,
Minneapolis, MN
BioXCell

CTLA4-Ig*

N/A

200 µg

Mouse IgG

CTLA4-Ig**

N/A

250 µg

Rat IgG

* Used in experiments in chapter 1
** Used in experiments in chapter 2
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Dr. Robert Mittler
(Department of
Surgery and Emory
Vaccine Center,
Emory University,
Atlanta, GA).
Sigma-Aldrich, St.
Louis, MO

Mouse IgG was from Sigma-Aldrich. Other isotype controls were obtained from BioXCell. All
antibodies except anti-CD54 and anti-CD178 were administered 2 h prior to SEA inhalation.
Anti-CD54 and anti-CD178 were given 36 h after SEA inhalation.

In vivo permeability assays
The in vivo permeability assays were performed using FITC-dextran similarly as described
before (107, 108). To assess lung permeability from lung to blood, mice received 50 µL of FITCdextran (3000 mW; 5 mg/mL; Life Technologies) i.n. and serum from tail blood was obtained 1 h
later. For blood into lung permeability assay, mice received 100 µL of FITC-dextran i.v. through
the retro-orbital route and BAL fluid was collected 1 h later. FITC fluorescence in the serum
(1:70) or BAL fluid (undiluted) was determined by a plate reader (483-14/530-30; CLARIOstar,
BMG LABTECH) and normalized either to the vehicle only-treated mice (Fig. 4-1) or the IgGtreated mice (Fig. 4-8).

Pan-caspase imaging
The amount of apoptosis in lung and spleen was detected by CAS-MAPTM near-infrared in vivo
fluorescent imaging probe (Vergent Bioscience, Minneapolis, MN) according to the
manufacturer’s instructions. Briefly, the by CAS-MAPTM probe was i.v. injected 60-90 min prior
to sacrifice. Lung and spleen were then imaged by Odyssey CLx Imager (LI-COR, Lincoln, NE).

Tissue harvest and processing
LNs and spleen
Airway-draining (mediastinal and cervical) and airway-non-draining LNs (axillary, brachial,
inguinal and mesenteric) were harvested. LNs and spleen were crushed and passed through a
100-µm strainer (Falcon/BD Biosciences). RBCs were lysed with ammonium chloride solution.
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BM
BM was flushed out with a 10 mL-syringe filled with BSS from one femur and tibia until no
remaining tissue was observed. The tissue was passed through a 100-µm strainer and RBCs
were lysed.
Peripheral blood
Mice were warmed up with a heat lamp for 3 min and peripheral blood was obtained by making
a small incision on their tail. For serum, the blood was collected into serum separator tubes (BD
Biosciences). For blood cells, 3-4 drops of blood were collected into BSS-heparin solution
(0.411g/L; Sigma-Aldrich). The cells were washed and RBCs were lysed with ammonium
chloride solution. This step was repeated to remove remaining RBCs.
Lung
Mice were sacrificed with an i.p. injection of ketamine. The lung tissue was perfused with PBS
by inserting a butterfly needle through the heart. Alternatively, in experiments in which BAL fluid
was collected, lung tissue was harvested without perfusion. The tissue was then dissected into
small pieces, placed in a conical flask containing 20 mL of collagenase solution (150 U/mL
collagenase (Sigma-Aldrich), 60 U/mL DNAse I (Sigma-Aldrich), 2% FBS, 1 mM Ca2Cl, 1 mM
Mg2Cl), and left spinning at 230 rpm for 30 min at 37°C. The tissue was passed through a 100µm strainer and RBCs were lysed with ammonium chloride solution and counted.
BAL fluid
The mice were sacrificed with an i.p. injection of ketamine. The thoracic cavity was exposed and
a small incision was made into the upper portion of the trachea. A syringe containing 2 mL of
PBS attached to polyethylene tubing (0.58x0.97 mm; Instech Laboratories, Inc., Plymouth
Meeting, PA) was inserted into the trachea and secured with a thread. The lungs were then
gently lavaged by injecting PBS into the tissue until fully expanded. The lavage was repeated 23 more times.
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Flow cytometry
Surface staining for flow cytometry was performed as described previously (30). Single cell
suspensions were counted with Z1 particle counter (Beckman Coulter, Brea, CA). Unspecific
binding was blocked with FcR blocking solution (culture supernatant from 2.4.G.2 hybridoma,
5% mouse serum (Sigma-Aldrich), 10 µg/mL human IgG (Sigma-Aldrich), 0.1% sodium azide)
and stained with antibodies and LIVE/DEAD® Fixable Blue Dead Cell Stain (Life Technologies,
Grand Island, NY) for 30-45 min on ice. For intracellular staining, cells were cultured with
brefeldin A (1 µg/mL; Calbiochem, San Diego, CA) and with or without PMA (50 ng/mL,
Calbiochem)/ ionomycin (1 µg/mL, Fisher Scientific) for 5 h. The cells were stained with surface
antibodies, fixed in 2% formaldehyde, permeabilized with 0.25% saponin and stained with
intracellular antibodies overnight at 4°C. Flow cytometry was performed using a FACS-LSRII
(BD Biosciences) and the data was analyzed with FlowJo software (Tree Star, Ashland, OR).
Antibody-stained positive cells were determined with corresponding isotype controls.
Fluorochrome-conjugated antibodies were obtained from BD Biosciences (San Jose, CA),
eBioscience (San Diego, CA), or BioLegend (San Diego, CA). The following fluorochromeconjugated antibodies were used:
TABLE 2-2: Flow cytometry antibodies and the clones.
Antibody
anti-CD3
anti-CD19
anti-CD8a
anti-B220
anti-NK1.1
anti-CD49b
anti-Ly6G
anti-Ly6C
anti-CD11c
anti-Vβ3

Clone
145-2C11 or
17A2
1D3
53-6.7
RA3-6B2
PK136
DX5
1A8
HK1.4
HL3 or N418
KJ25

anti-Vβ14
anti-CD25
anti-CD69
anti-MHC II
anti-F4/80
anti-CD103
anti-CD11b
ant-CD45.2
(shown as
CD45)
anti-CD31
anti-CD54

14-2
PC61
H1.2F3
M5/114.15.2
BM8
2E7
M1/70
104

390
YN1/1.7.4

20

antigranzyme B
anti-CD95
anti-CD11a
anti-IFN-γ
anti-SIGLEC
F
anti-CD169

NGZB
Jo2
H155-78
XMG1.2
E50-2440
SER-4

Staining for SEA was performed with polyclonal anti-SEA antibody produced in rabbit (whole
antiserum; Sigma-Aldrich) followed by secondary rabbit IgG Alexa Fluor 488 (Life
Technologies).

Cell sorting
For T cell sorting, LNs (cervical, mediastinal, axillary, brachial, inguinal, and mesenteric)
were collected and processed as described above. For sorting of dendritic cells (DCs), the
LN tissue was digested with collagenase solution (150 U/mL collagenase (Sigma-Aldrich),
2% FBS in MEM) for 30 min at 37°C and 5% CO2. After tissue digestion, 100 µL of 0.1M
EDTA in PBS per 1 mL of collagenase solution was added. The tissue was then passed
through a 100-µm strainer and washed in 5 mM EDTA and 2% FBS Ca2+/Mg2+ free BSS. For
endothelial cell sorting, lung tissue was prepared as described above. After FcR blocking
and antibody staining, cells were sorted with FACS Aria (BD Biosciences).

CyTOF
Lungs were obtained from mice 14 or 40 h after SEA or vehicle inhalation, digested with
collagenase/DNAse solution and purified using Lympholyte M (Cedarlane Labs, Burlington,
NC). Each one of the 4 samples was labeled with Cell-IDTM Cisplatin to identify live and
dead cells and subsequently barcoded with Cell-IDTM Pd Barcoding kit (all CyTOF reagents
are from Fluidigm, San Francisco, CA). The 4 samples were pooled together, permeabilized
with methanol, and incubated with Fc receptor blocking solution and 24 heavy metalconjugated antibodies, including 7 signaling markers. DNA was labeled using Cell-IDTM
Intercalator-Ir. The pooled sample was spiked with normalization beads and analyzed by a
mass cytometer (Helios, Fluidigm). The data were de-barcoded using the Fluidigm
Debarcoder v1.04. A single cell and live cell gate were obtained from each sample. The
samples were further sub-gated to include the same number of cells per sample and
merged to create ViSNE maps (MATLAB, MathWorks, Natick, MA) using only the non-

21

signaling markers. Histograms comparing the expression of signaling and activation markers
were generated using MATLAB. Median intensity values were obtained by FlowJo software.

Co-culture assays
To obtain naïve T cells, spleen and LNs were harvested from a naïve mouse and processed
as described above. To enrich the population of Vβ3+ T cells, the cells were depleted using
anti-B220 clone RA3-6B2, anti-NK1.1 clone PK136, anti-Vβ2 clone B20.6, anti-Vβ4 clone
KT-4, anti-Vβ5.1,5.2 clone MR9-4, anti-V6β clone RR4-7 and anti-Vβ8 clone F23.1 biotinconjugated antibodies (eBioscience and BD Biosciences) and anti-biotin magnetic beads
(Miltenyi Biotec Inc, Auburn, CA). For co-culture of T cells with serum or blood cells, tail
blood was obtained 10 or 30 min after SEA or vehicle inhalation into either heparincontaining BSS or serum separator tubes (BD Biosciences). Blood cells were processed as
described above. Next, the enriched T cells (100,000/well) were incubated with either cells
derived from the blood (25,000/well) or the isolated serum (diluted 1:4 in culture medium)
overnight at 37°C and 5% CO2. For co-culture of T cells with DC subpopulations, LNs
(mediastinal, cervical, axillary, brachial, inguinal) were collected 40 min after SEA or vehicle
inhalation and processed as described above. The cells were enriched for DCs by depleting
B220+ and Thy1.2+ cells using Dynabeads (Life Technologies), stained and sorted. The
sorted DC subpopulations (5,000/well) were incubated with naïve enriched T cells
(20,000/well) overnight at 37°C and 5% CO2. After the culture, supernatants were collected
to measure IL-2 concentration by ELISA (BD Biosciences) and the cells were washed and
stained for flow cytometry as described above.

ELISA and multiplex assays
Serum was obtained from tail blood by using the serum separator tubes (BD Biosciences).
BAL fluid was collected as described above. The isolated serum and BAL fluid were stored
at −80°C. ELISAs for albumin (Bethyl Laboratories, Montgomery, TX), CD54, angiopoietin-2,
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receptor for advanced glycation end products (RAGE), granzyme B (R&D Systems) and
cytokine ELISAs for IL-6, TNF and IFN-γ (BD Biosciences) were performed according to the
manufacturer’s instructions.
For the multiplex assay of LN lysates (see chapter 3), LNs were isolated from mice 4 or 16 h
after SEA or vehicle exposure. The tissue was placed in MagNA Lyser green beads tubes
(Roche, Basel, Switzerland) filled with 400 µL PBS containing Protease Inhibitor Cocktail
(Sigma-Aldrich) and lysed using MagNA Lyser Instrument (Roche) at 6,000 rpm for 1 min.
The lysates were stored in −80°C. Chemokine and cytokine expressions were measured
with customized Luminex® -based multiplex assay (EMD Millipore, Billerica, MA). The
expression of individual chemokines and cytokines was normalized to the protein
concentration measured by the Pierce BCA protein assay kit (Thermo Scientific, Rockford,
IL). Bio-Plex Pro™ Mouse Cytokine 23-plex Assay (Biorad) was used to measure the time
course of cytokine and chemokine release in serum and BAL fluid (see chapter 4).

Quantitative real-time PCR and RNA sequencing
For quantitative real-time PCR (qRT-PCR) analyses of the whole tissue, LNs from SEA or
vehicle-exposed mice were removed, frozen on dry ice and stored at −80°C. To acquire
RNA, the whole tissue was snap-frozen in liquid nitrogen and crushed into powder. The total
RNA was isolated from the LN tissue or sorted cells with RNeasy Mini Kit (Qiagen, Valencia,
CA) and converted to cDNA using iScript cDNA Synthesis Kit (Biorad, Hercules, CA). mRNA
expression level of target genes and the endogenous control gene β-actin or Gapdh were
assessed by real-time PCR using Taqman primers (Life Technologies) and a CFX96 RealTime PCR instrument (Biorad). Each sample was run in duplicate and the gene expression
was normalized to β-actin or Gapdh using the standard curve method.

For RNA sequencing, total LN cells (isolated from cervical, mediastinal, axillary, brachial,
inguinal, and mesenteric LNs) were collected 40 min after SEA or vehicle inhalation. The
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cells were sorted and mRNA was acquired as described above. Total RNA was sequenced
(Otogenetics, Norcross, GA) and transcriptomes from SEA Vβ3+ T cells were compared to
transcriptomes from vehicle Vβ3+ T cells and SEA Vβ14+ T cells (control groups). Genes in
SEA Vβ3+ cells that were downregulated (log2 fold change ≤ −1.5) or upregulated (log2 fold
change ≥ +1.5) were compared to control groups in all three experiments were selected.
The selected list of genes was further examined and any genes with inconsistent or close to
zero expressions removed. Gene expressions patterns in the selected genes were analyzed
using Gene set enrichment analysis (GSEA, Broad Institute, Cambridge, MA). The following
gene set databases were used: h.all.v5.0.symbols.gmt and c5.all.v5.0.symbols.gmt
(http://www.broadinstitute.org/gsea/msigdb/index.jsp). To construct heat maps, gene
expressions were corrected to log2 and processed using GENE-E software (Broad Institute).
The RNA sequencing data can be viewed online (http://www.ncbi.nlm.nih.gov/geo/;
accession number: GSE76190).

Confocal microscopy
Whole cervical LNs or lung was fixed in periodate-lysine-paraformaldehyde (PLP) solution (1
µM sodium periodate, 75 mM L-lysine, 1% paraformaldehyde in phosphate buffer) at 4°C
overnight. The tissue was washed in phosphate buffer, left in 30% sucrose at 4°C overnight,
frozen in OCT and stored at −80°C. The frozen tissue was cut into 20 µm-thick sections with
LEICA CM1850 cryostat (Leica Biosystems, Buffalo Grove, IL) and the sections were stored
at −20°C. For antibody staining, the sections were firstly blocked for unspecific binding using
a staining buffer (either 2% FBS in PBS or 2% FBS, 2% goat serum, 0.5% FcR blocking
solution, 0.05% Tween-20, 0.3% Tritone-X100 in PBS) for 1 h at RT and then stained with
primary antibodies diluted in the staining buffer for 1 h at RT. The sections were examined
with Zeiss LSM780 confocal microscope mounted on an inverted Axio Observer Z1 (Zeiss,
Oberkochen, Germany). Immunofluorescent staining was performed with the following
antibodies: DyLight 488-conjugated anti-Ly6B.2 clone 7/4 (labeled as 7/4; Novus
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Biologicals, Littleton, CO), V450-conjugated anti-CD11b clone M1/70, PE-conjugated antiVβ3 clone KJ25, allophycocyanin-conjugated anti-CD11c clone HL3, PE-conjugated antiactive caspase-3 clone C92-605 (all from BD Biosciences), eFlour 660-conjugated antiCD169 clone SER-4, allophycocyanin-conjugated MHC II clone M5/114.15.2 ( both from
eBioscience). SEA staining was performed with polyclonal anti-SEA antibody (whole rabbit
antiserum; Sigma-Aldrich) followed by Alexa Flour 488-conjugated anti-rabbit IgG staining. B
cell follicles in LNs were determined with Pacitic Orange-conjugated anti-B220 clone RA36B2 (not shown in images; Life Technologies). The images represent confocal z-stack
projections, which were acquired using 20×/0.8 numerical aperture objective. Image
analysis, including adjustment for contrast and brightness and cellular quantification, was
done with Imaris software (Bitplane, Zurich, Switzerland). The number of active caspase-3+
cells in the SEA-exposed mice was only determined in loci of increased inflammation (areas
with an increased number of inflammatory cells). No such areas were found in the vehicle
control. Colocalization studies that measured the percentage of cells positive for multiple
markers were completed by Imaris with threshold value for colocalization set to 7.

Statistical analysis
The following tests were used to determine statistical significance (p<0.05): one-way
ANOVA (with Dunnett’s or Tukey’s multiple comparisons tests), two-way ANOVA (with
Sidak’s multiple comparisons test), two-tailed Student’s unpaired t test or paired t test. All
statistical tests were performed using Prism-GraphPad (La Jolla, CA) and Microsoft Excel.
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Chapter 3: Systemic Inflammatory Response Following S. aureus Enterotoxin
A Inhalation

This work was published in the Journal of Immunology, vol. 196, issue 11, pp. 4510-4521,
June 1, 2016 under the title “TNF and CD28 Signaling Play Unique but Complementary
Roles in the Systemic Recruitment of Innate Immune Cells after Staphylococcus aureus
Enterotoxin A Inhalation” and was authored by: Julia Svedova, Naomi Tsurutani, Wenhai
Liu, Kamal M. Khanna, and Anthony T. Vella.
Some modifications to the original text were done to accommodate additional figures and
tables used to supplement this chapter.

Copyright 2016. The American Association of Immunologists, Inc.

Abstract

Staphylococcus aureus enterotoxins cause debilitating systemic inflammatory responses,
but how they spread systemically and trigger inflammatory cascade is unclear. Here, we
showed in mice that after inhalation, Staphylococcus aureus enterotoxin A rapidly entered
the bloodstream and induced T cells to orchestrate systemic recruitment of inflammatory
monocytes and neutrophils. To study the mechanism used by specific T cells that mediate
this process, a systems approach revealed inducible and non-inducible pathways as
potential targets. It was found that TNF caused neutrophil entry into the peripheral blood,
while CD28 signaling, but not TNF, was needed for chemotaxis of inflammatory monocytes
into blood and lymphoid tissue. However, both pathways triggered local recruitment of
neutrophils into lymph nodes. Thus, our findings revealed a dual mechanism of monocyte
and neutrophil recruitment by T cells relying on overlapping and non-overlapping roles for
the non-inducible costimulatory receptor CD28 and the inflammatory cytokine TNF. During
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sepsis, there might be clinical value in inhibiting CD28 signaling to decrease T cell-mediated
inflammation and recruitment of innate cells while retaining bioactive TNF to foster
neutrophil circulation.

Introduction

Staphylococcus aureus (S. aureus) is a part of normal human flora colonizing skin,
nasopharynx and most commonly the anterior nares of the nose in almost 30% of the
general population (11). A recent epidemiological study showed that Gram-positive bacteria
were found in 47% of intensive care unit patients with an infection, with S. aureus present in
20% of positive cultures (77). Infection and related sepsis are one of the leading causes of
death in the United States (3). Sepsis, characterized as systemic inflammatory response
syndrome (SIRS) with a known or suspected infection, is a result of a dysregulated immune
response, commonly accompanied by an uncontrolled release of cytokines that can lead to
systemic tissue injury, shock and even death (7). Methicillin-resistant S. aureus is
particularly well spread in hospital settings and is associated with key virulence factors that
may contribute to the severity and rapidity of sepsis (13). One such virulence factor is
superantigens, such as S. aureus enterotoxins. These are heat resistant proteins that
bypass classical antigen processing and presentation to mediate powerful oligoclonal T cell
receptor Vβ chain-specific responses (110, 111) leading to toxic shock syndrome and
potentially death (32, 112-114).
A recent study showed that the presence of an enterotoxin was essential for the
lethality of S. aureus-induced sepsis in rabbits (85). In addition, superantigens can synergize
with TLR4 or TLR2 agonists and enhance the inflammatory response and the induction of
lethal shock in mice (115, 116). Superantigens have been found in blood of septic patients
and their prevalence, in particular prevalence of S. aureus enterotoxin A (SEA), was
correlated with severity of infection (79, 80, 117). Therefore, it is likely that the presence of
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S. aureus enterotoxins drives or at least significantly exacerbates the inflammatory response
in septic patients. It is still unclear, however, how S. aureus enterotoxins spread systemically
especially in cases of an unknown entry point and how they trigger both adaptive and innate
immunity to propagate systemic inflammation.
Mice exposed to S. aureus enterotoxins reproduce several important hallmarks of
SIRS/sepsis in humans, including a rapid-onset immune response with a robust cytokine
release (10, 111) and an immunosuppression/anergy phase (52, 118, 119) similar to the
compensatory anti-inflammatory response syndrome (CARS) that often occurs in septic
patients (120). Furthermore, SEA inhalation also recapitulates a common complication in
sepsis, acute lung injury. The lungs of exposed mice show elevated proteins, presence of
red blood cells and increased levels of cytokines (39, 106). Using the SEA model of SIRS,
we sought to study systemic immune responses occurring immediately after SEA
administration. The pulmonary SEA challenge resulted in a rapid release of monocytes and
neutrophils to blood and their accumulation in lymphoid tissues. Remarkably, this
inflammatory innate cell migration was dependent on the presence of T cells. In particular,
the systemic recruitment of monocytes and neutrophils was dually regulated by T-cell based
CD28 signaling and the inflammatory cytokine TNF.

Results

Systemic recruitment of monocytes and neutrophils is observed rapidly after SEA
inhalation
SEA inhalation results in alveolitis characterized by increased protein content,
presence of RBCs, secretion of cytokines, and accumulation of monocytes and neutrophils
(30, 39). The local lung response is coincident with an expansion of SEA-specific T cells in
all lymphoid tissues (39). To understand how SEA inhalation causes a systemic response,
serum and blood cells were isolated immediately after SEA or vehicle challenge and
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incubated with enriched naïve T cells. Cells derived from blood after SEA or vehicle
inhalation and serum from vehicle mice did not affect T cell activation (Fig. 3-1, A and B;
data not shown). However, serum obtained only 10 min after SEA inhalation was able to
activate SEA-specific Vβ3+ T cells to express CD69 and CD25 while having little effect on
bystander Vβ14+ T cells (Fig. 3-1, A and B). The same type of response was observed when
the naïve T cells were incubated with SEA (Fig. 3-2). Finally, only T cells co-cultured with
serum from SEA mice produced IL-2 (Fig. 3-1, C). To estimate the amount of SEA that was
found in the serum upon inhalation, enriched naïve T cells were co-cultured with increasing
concentrations of SEA overnight and the level of T cell activation was assessed by flow
cytometry. Fig. 3-2 represents titration curves of CD69 and CD25 expression on SEAspecific Vβ3+ T cells and bystander Vβ14+ T cells. The titration curves were then used to
extrapolate the concentration of SEA in the serum of mice 10 min after SEA inhalation
(dotted line – value obtained from Fig. 1A and B). Because the serum was diluted 1:4 when
added to culture, the concentration of SEA in the serum was estimated to be between ~12
and 28 ng/mL of blood (Fig. 3-2; red arrow values multiplied by 4). Interestingly, this
concentration was only a fraction of the amount administered i.n. to each mouse (1 µg).
Thus, SEA can rapidly enter the bloodstream after inhalation in small but sufficient quantities
to activate T cells.
The rapid spread of the enterotoxin after inhalation through blood posed the question
of whether the systemic inflammatory response to SEA was accompanied by a common
hallmark of SIRS and sepsis, blood leukocytosis (7). To test if SEA inhalation mediates
systemic circulation of innate immune cells, mice were challenged with SEA or vehicle alone
and then the peripheral blood cells were analyzed for the presence of monocytes or
neutrophils. Inflammatory monocytes were identified as CD3−CD19−CD11b+Ly6G-Ly6Chi
while neutrophils were identified as CD3−CD19−CD11b+Ly6G+Ly6C+ (Fig. 3-3, A). The
percent of neutrophils in blood increased 6.4-fold 2 h after SEA challenge compared to
vehicle while there was no relative increase in monocytes (Fig. 3-3, B). Nevertheless, both
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populations were increased 4 h after SEA inhalation. SEA-based inflammation is dependent
on T cells, which are found in lymphoid tissues (39). Therefore, it was hypothesized that the
circulating inflammatory innate cells would migrate to the LNs and spleen. Indeed, the
percent of inflammatory monocytes and neutrophils at 4 h after SEA inhalation was
increased in spleen, mediastinal, cervical, and non-draining LNs compared to vehicle control
(Fig. 3-3, C). Inflammatory monocytes remained elevated at 12 h whereas the percent of
neutrophils decreased to the level of vehicle-treated mice. Like percentages, the same
trends were observed when assessing the absolute numbers of inflammatory monocytes
and neutrophils (data not shown). The recruited monocytes likely originated from the BM
because there was a depletion of BM inflammatory monocytes reaching over 50% reduction
compared to the vehicle control by 4 h after SEA inhalation (Fig. 3-3, D). Interestingly, SEA
challenge caused only a small decline in the number of BM neutrophils. In sum, SEA
inhalation resulted in rapid systemic recruitment of monocytes and neutrophils to blood and
lymphoid tissues.

The recruitment of innate immune cells after SEA inhalation is guided by T cells to the
T cell zone of the LNs
SEA inhalation induces monocyte and neutrophil migration to lungs in a T cell
dependent manner (30). To determine the role of T cells in the systemic recruitment of
innate immune cells to blood and LNs, TCR βδ−/− mice, that lack both αβ and γδ T cells,
received C57BL/6J T cells or nothing and subsequently, they were i.n. challenged with SEA
or vehicle. In the absence of T cell transfer, cervical LNs and blood from SEA-treated mice
showed no difference in accumulation of monocytes or neutrophils compared to the vehicle
group (Fig. 3-4). However, SEA-challenged TCR βδ−/− mice that received T cells had
significant increases in the percent of both monocytes and neutrophils compared to vehicle
alone (Fig. 3-4). Thus, T cells were required to trigger the systemic recruitment of
inflammatory innate immune cells to blood and LNs after inhalation of SEA.
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Migration of neutrophils and monocytes to LNs was previously reported (121-127).
However, while some studies showed that following an infection or antigen challenge,
neutrophils were recruited to the subcapsular sinus (121, 124), others found innate immune
cells in the T cell zone (125, 127). To determine where the recruited cells accumulated,
cervical LNs were collected 1, 2, and 4 h after SEA inhalation and examined by confocal
microscopy. Inflammatory innate immune cells (CD11b+7/4+) were detected in the LNs as
early as 2 h after SEA but not in the vehicle control (Fig. 3-5, A). By 4 h, the quantity of
inflammatory innate immune cells increased even further, which was confirmed by
enumerating 7/4+ cells per field (Fig. 3-5, B). Importantly, the recruited cells were primarily in
the T cell zone of the LNs whereas the few inflammatory cells in the vehicle alone mice were
mostly located in the subcapsular sinus and B cell follicles (Fig. 3-5, C). These findings
demonstrate that SEA inhalation induced recruitment of monocytes and neutrophils
particularly to the T cell zone in the LNs where the SEA-specific T cells become activated.

SEA inhalation triggers a rapid release of specific chemokines by both T cells and
dendritic cells
Monocyte and neutrophil migration can be driven by a number of chemokines (128130). To understand which chemotactic factors might play a role in the systemic recruitment
of monocytes and neutrophils, total RNA was isolated from draining LNs (cervical and
mediastinal) to assess the expression of various chemokine genes. Compared to vehicle,
expression of multiple chemotactic factors increased as early as 1 h after SEA inhalation
(Suppl. Fig. 2A). Interestingly, mRNA levels of chemokines particularly important for the
recruitment of neutrophils and monocytes – Cxcl1, Cxcl2, Ccl2, Ccl3, Ccl4, and Ccl7 (128,
130) showed a rapid increase in expression peaking at 2 h (Fig. 3-6, A; clear bar graphs).
To validate these findings, LN lysates were examined for the protein levels of these
chemokines by a multiplex assay. Multiple chemokines were significantly elevated 4 h after
SEA inhalation, including 38-fold for CXCL1, 792-fold for CXCL2, 53-fold for CCL2, 46-fold
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for CCL3 and 92-fold for CCL4 (Fig. 3-6. B). Nevertheless, the increased chemokine levels
were transient because by 16 h after SEA challenge, they were already decreasing. In
addition, the expression of chemotactic factors was systemic as SEA challenge caused a
similar increase in chemokine levels in draining LNs, peripheral LNs, and mesenteric LNs
(data not shown). We previously showed that SEA-activated αβ T cells directed γδ T cells to
release IL-17, which contributed to the recruitment of neutrophils to lungs after SEA
inhalation (30). Therefore, we assayed for IL-17, but only a small increase was detected in
the LN lysates of the SEA group compared to vehicle (Fig. 3-6, B, bottom panel).
Because SEA can directly crosslink MHC class II (MHC II) molecules on antigenpresenting cells and Vβ chains of the TCR (22), we hypothesized that DCs and T cells were
an important source of chemokines recruiting monocytes and neutrophils. Therefore,
Lin−CD11c+MHC II+ DCs were sorted and the relative expression of chemokines was
determined. DCs from SEA-challenged mice upregulated Cxcl1 and Cxcl2 mRNA levels but
not Ccl3 and Ccl4 compared to DCs from the vehicle group (Fig. 3-7, A). Interestingly, SEAactivated Vβ3+ T cells but not bystander Vβ14+ T cells substantially expressed Ccl3 and
Ccl4, in particular, 680-fold and 738-fold increases compared to vehicle, respectively (Fig. 37, B). DCs are heterogeneous and thus, to understand if a specific subset was critical,
CD11clowMHC IIhi migratory DCs and CD11chiMHC IIlow resident DCs (131, 132) were sorted
(Fig. 3-7, C). Migratory DCs expressed more Cxcl1 and Cxcl2 as normalized to β-actin
expression than the resident DCs (Fig. 3-7, D). To summarize, SEA inhalation induced rapid
production of chemokines by SEA-activated T cells and DCs (predominatly migratory DCs).
To see if the differential chemokine expression in the DC subpopulations was due to
their ability to present SEA, we tested if either migratory DC (Lin−CD11clowMHC IIhi) or
resident DC (Lin−CD11chiMHC IIlow) subpopulations were preferentially stimulating the SEAspecific T cells. In particular, four distinct DC subpopulations were sorted from either SEA or
vehicle-immunized mice (Fig. 3-8, A) and without adding SEA, the sorted DC
subpopulations were cultured with naïve T cells. Both CD11b+ and CD103+ migratory DCs
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from the SEA-immunized mice, but not resident DCs, activated Vβ3+ T cells to upregulate
CD69 (Fig. 3-8, B). There was no difference in CD69 expression on the bystander Vβ14+ T
cells when cultured with DCs from SEA-immunized mice compared to the vehicle control.
These findings show that that only migratory DCs presented SEA ex vivo to naïve SEAspecific T cells.

Mechanism of T cell guided innate cell recruitment
To determine the mechanism of how SEA-activated T cells promote chemokine
production by DCs, SEA-specific Vβ3+ and bystander Vβ14+ T cells were sorted 40 min after
SEA or vehicle inhalation and RNA was isolated for transcriptome analysis (Fig. 3-9, A).
Comparing RNA from SEA Vβ3+ T cells to vehicle Vβ3+ or SEA Vβ14+ control groups, many
genes were found to be upregulated in the SEA-specific Vβ3+ T cells (Fig. 3-9, B; Table 3-1).
Gene expression increases were predominantly associated with cell development,
proliferation, and regulation of metabolic processes. However, GSEA also revealed a
significant association with apoptosis and negative regulation of cells (Fig. 3-9. C). In
addition, both pro- (Tnf, Il2, Ifng) and anti-inflammatory cytokines (Il10) were upregulated in
Vβ3+ T cells from the SEA-treated group suggesting a role for T cell costimulation (Fig. 3-9,
D).
The expression of inducible as well as constitutively expressed costimulatory
molecules were compared. While there was no difference in the expression of constitutively
expressed costimulatory molecules, five inducible costimulatory molecules were significantly
upregulated in SEA Vβ3+ T cells, including 4-1BBL (Tnfsf9), LIGHT (Tnfsf14), CD40L
(Cd40lg), SLAM (Slamf1), and TWEAK receptor (Tnfrsf12a) (Fig. 3-9, E and F).
Interestingly, inducible coinhibitory molecules, particularly PD-L1 (Cd274), PD-L2
(Pdcd1lg2), and PD1 (Pdcd1), were also upregulated in SEA Vβ3+ T cells compared to the
control groups (Fig. 3-9, G and H), further confirming the dual capacity of T cells to promote
and suppress inflammation immediately after SEA inhalation.
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Previous studies found that 4-1BB-4-1BBL and CD40-CD40L pathways can enhance
the recruitment of innate immune cells (133, 134). Furthermore, 4-1BBL and CD40L
expression on Vβ3+ T cells was validated by flow cytometry (data not shown). Therefore, it
was hypothesized that the systemic migration of innate immune cells might be dependent on
the expression of inducible costimulatory molecules. To determine whether 4-1BBL and
CD40L play a role in the migration of monocytes and neutrophils, mice were pre-treated with
anti-4-1BBL, anti-CD40L or the corresponding IgG control and then i.n. challenged with
SEA. Neither 4-1BBL nor CD40L blockade impeded migration of monocytes or neutrophils
to blood and LNs (Fig. 3-10, A and B), suggesting other mechanisms were involved.
One possibility is that a constitutively expressed costimulatory molecule, such as
CD28, might be responsible for this recruitment. The membrane receptor CD28 engages its
ligands CD80 and CD86 on DCs and potently enhances TCR-induced cytokine release and
proliferation of naïve T cells (135, 136). In addition, CD28 engagement is needed for optimal
superantigen-induced T cell expansion (137). Consistent with this previous work, genes
associated with CD28 signaling (138-140) were upregulated in Vβ3+ T cells after SEA
inhalation (Table 3-2). Secondly, cytokines like TNF and IL-2 are major factors released by
enterotoxin-specific T cells (32, 141) and our data show that Tnf is promptly synthesized by
SEA-specific Vβ3+ T cells (Fig. 3-9. D). Furthermore, GSEA of the hallmark pathways
demonstrated a significant enrichment in the pathway of TNF signaling via NFκB in the SEAspecific Vβ3+ T cells (Fig. 3-11, A). Thus, it was hypothesized that CD28 costimulation and a
cytokine played redundant or non-overlapping roles in innate cell recruitment in SEAtriggered acute inflammation.
To test this notion, CD28 and TNF were neutralized in SEA-treated mice with
CTLA4-Ig or anti-TNF. First, we tested whether CD28 or TNF neutralization affected serum
IL-6 levels since increased IL-6 correlates with decreased survival not only in models of
sepsis but also in septic patients (142-145). Both, CTLA4-Ig and anti-TNF significantly
reduced serum IL-6 compared to the IgG controls, with anti-TNF being even more effective
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in decreasing IL-6 than CTLA4-Ig (Fig. 3-11, B). Thus, both treatments appeared to
attenuate inflammation by reducing serum IL-6 levels.
To assess whether CD28 or TNF orchestrate monocyte and neutrophil chemotaxis
after SEA inhalation, LN tissue from CTLA4-Ig or anti-TNF treated-mice was examined for
the expression of chemokines. While CTLA4-Ig significantly reduced Cxcl1, Cxcl2, Ccl2,
Ccl3, and Ccl7 mRNA expression, anti-TNF only decreased Cxcl2 expression and had no
significant effect on the other chemokines (Fig. 3-11, C). These findings suggested that
CTLA4-Ig would be more effective in blocking the systemic recruitment of monocytes and
neutrophils compared to anti-TNF. Indeed, the percent of inflammatory monocytes in LNs
and blood was significantly reduced after CTLA4-Ig treatment. In contrast, anti-TNF
relatively increased the percent of monocytes in the blood but had no effect on their
migration to LNs (Fig. 3-11, D). Nevertheless, both CD28 and TNF blockade significantly
reduced the accumulation of neutrophils in LNs (Fig. 3-11, E, upper panels). Based on the
results from Fig. 3-3, B, which demonstrated robust migration of neutrophils and monocytes
into the bloodstream after SEA inhalation, it was tested if these pathways operated by
preventing migration of innate cells into blood. CTLA4-Ig did not inhibit neutrophil circulation
(Fig. 3-11, E, lower left panel), but interestingly, TNF blockade significantly inhibited
recruitment of neutrophils into blood (Fig. 3-11, E, lower right panel). These findings posed
the question of whether the reduction of neutrophils in the LNs after anti-TNF treatment was
due to the decreased circulation of blood neutrophils (Fig 1-11, E, lower panels) or reduced
Cxcl2 expression (Fig. 3-11, C). In TNF blocked mice, there was no correlation between the
percentage of neutrophils in the blood versus the LNs (Fig. 3-11, F). However, mRNA Cxcl2
expression positively correlated with the percentage of neutrophils in the LNs suggesting
that migration into LNs was dependent on a chemokine gradient rather than the amount of
circulating cells (Fig. 3-11, G). Thus, the systemic recruitment of monocytes and neutrophils
after SEA inhalation is orchestrated by a non-inducible CD28 signal with overlapping and
non-overlapping roles for TNF.
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Discussion

Staphylococcus aureus enterotoxins have been implicated in the pathology of toxic
shock, sepsis as well as a number of pulmonary and autoimmune diseases due to their
ability to elicit a massive and systemic cytokine storm (10, 78, 95, 146). However, it is
unclear how S. aureus enterotoxins enter the periphery to instigate these effects since the
lungs and airways are usually impermeable to inhaled antigens. In fact, antigens are
typically cleared from these tissues by a number of mechanisms, including mucociliary
transport, innate defense molecules and resident phagocytes (147, 148). Alternatively,
inhaled antigens can be carried by migratory DCs to the draining LNs where they are
presented to antigen-specific T cells, a process that occurs over hours (147, 149). Unlike
most antigens, we demonstrate in this report that inhaled SEA enters the blood circulation
within minutes and can be recovered in the serum rather than associated with cells (Fig. 31). This ability to enter the bloodstream while maintaining its full bioactivity accounts for the
rapid systemic response observed after S. aureus enterotoxin pulmonary exposure (30, 39).
From a biomedical perspective, our study showed that just as seen in many patients
with SIRS/sepsis (150), SEA inhalation induced leukocytosis since the pulmonary SEA
challenge initiated rapid recruitment of innate immune cells to blood followed by their
migration to lymphoid tissues (Fig. 3-3). During inflammation, innate immune cells are often
assumed to originate from BM. While the pool of inflammatory monocytes in the BM was
markedly depleted, there was only a small decrease in BM neutrophils after SEA inhalation
(Fig. 3-3, C). A second neutrophil reservoir is the marginated pool where the egress of
neutrophils is much faster than the BM peaking at 2 h after an injection of a stimulant (151).
The large increase in circulating neutrophils 2 h after SEA inhalation suggests that many of
the recruited neutrophils originated from the marginated pool rather than BM.
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Activation and expansion of T cells has been considered the core of S. aureus
enterotoxin-induced inflammation (10). Nevertheless, several studies reported that an
inflammatory response could occur even in the absence of T cells (152, 153). In the inhaled
SEA model of SIRS, TCR βδ−/− mice were unable to recruit monocytes and neutrophils to
blood and LNs whereas only a small transfer of T cells induced a rapid mobilization of the
innate cells (Fig. 3-4). The recruited cells localized to the T cell zone of the LNs (Fig. 3-5).
This specific location in the LNs renders an opportunity to modulate adaptive immunity.
Previous studies showed that after recruitment to LNs, inflammatory monocytes differentiate
into DCs and are capable of antigen presentation, including cross-presentation, resulting in
enhanced Th1 responses via IL-12 (126, 127). Similarly, neutrophil migration to LNs has
been associated with several different functions, including carrying bacteria to LNs via the
lymphatic system, augmenting lymphocyte proliferation, and downregulating CD4 T cell
responses by decreasing antigen presentation by antigen-presenting cells (122, 124, 154).
Thus, it will be important to determine if the migration of inflammatory monocytes and
neutrophils to the T cell zone of LNs affects the function of T cells and the overall
inflammatory response after pulmonary S. aureus enterotoxin challenge.
To test whether the recruitment of innate immune cells was caused by mediators
directly released by T cells, we examined T cells for chemokine expression and found that
upon activation, T cells expressed chemokines but also induced chemokine expression in
DCs (Fig. 3-7). This was coincident with increases in inducible costimulatory pathways
rapidly after SEA inhalation that included Tnfsf9 (4-1BBL) and Cd40lg (CD40L) (Fig. 3-9, E
and F). However, while inducible costimulation was not involved in the monocyte and
neutrophil chemotaxis (Fig. 3-10), blocking non-inducible CD28 costimulation significantly
reduced the migration of inflammatory monocytes (Fig. 3-11). In contrast, neutrophil
recruitment was driven by two T cell-dependent signals. Firstly, TNF triggered a rapid
release of neutrophils into blood, which we postulate is derived from the marginated pool.
Secondly, a chemokine axis induced by both the CD28 and TNF pathways directed
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neutrophils to LNs (Fig. 3-11, E). In particular, the inhibition of neutrophil migration to LNs
was coincident with reduced expression of Cxcl2 (Fig. 3-11, C and D) and it was previously
reported that the migration of neutrophils into tumor-draining LNs via high endothelial
venules was dependent on CXCL2 but not on CXCL1 (125). Therefore, we hypothesize that
CXCL2 may be the key chemokine driving the neutrophil migration into LNs from blood after
pulmonary challenge with S. aureus enterotoxins or during Gram-positive sepsis. Finally, we
showed that T cells were essential for the systemic recruitment of neutrophils and
monocytes after SEA inhalation (Fig. 3-4). However, because TNF can be produced by
many cell types (155) and CD28 expression was reported on immune cells other than T
cells (156, 157), it is possible that blocking with CTLA4-Ig and anti-TNF affected other cell
populations that could also contribute to the reduced migration of innate cells.
Despite decades of research, there is currently no approved drug treatment for
SIRS/sepsis patients (7). Because of the central role TNF plays in the pathology of
SIRS/sepsis, anti-TNF therapies were previously thought to be an excellent therapeutic
target (158). However, clinical studies failed to find improvements in the outcomes of
patients with sepsis receiving anti-TNF treatment (159-161). Moreover, rheumatoid arthritis
patients on anti-TNF therapy gained a higher likelihood of developing serious infections
(162). Our results show that although TNF blockade attenuated inflammation by reducing
serum IL-6 (Fig. 3-11, B), it also significantly depleted the pool of circulating blood
neutrophils (Fig. 3-11, E). The capacity of neutrophils to mount a rapid microbicidal
response makes them a crucial component of the immune system during sepsis. In fact, the
relative resistance to S. aureus in C57BL/6 mice was recently attributed to increased
chemokine secretion and subsequent neutrophil recruitment compared to other mouse
strains (163). In addition, reduced levels of circulating neutrophils may be associated with a
decreased likelihood of survival in sepsis (142, 164). The suppressed neutrophil levels in
blood could potentially compromise the immune system’s capacity to kill off bacteria in the
bloodstream. Therefore, it is possible that the failure of anti-TNF therapies to ameliorate
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outcomes in sepsis is partially due to the reduced neutrophil count in blood leading to
increased bacteremia.
Costimulatory molecules represent another group of potential therapeutic targets in
SIRS/sepsis. In particular, CD28 may play an important role in the propagation of
inflammation during the course of the disease. A clinical trial using a monoclonal
superagonist anti-CD28 resulted in a life-threatening SIRS with clinical signs and symptoms
similar to sepsis (165). In contrast, blocking CD28 signaling, especially in cases of
superantigen-induced toxic shock, showed attenuation of the disease in mice (166, 167).
Here we showed that blocking CD28 reduced IL-6 levels and chemokine expression, while
impeding migration of monocytes and neutrophils to LNs without affecting neutrophilia in
blood (Fig. 3-11). Therefore, targeting CD28, especially in cases of Gram-positive sepsis in
which S. aureus enterotoxins may drive the pathology, merits further investigation.
Lastly, not only costimulatory but also coinhibitory molecules, particularly Cd274
(PD-L1), Pdcd1lg2 (PD-L2) and Pdcd1 (PD1), were upregulated after SEA inhalation (Fig. 39). Similarly, both pro- and anti-inflammatory cytokines were upregulated as were the
processes of cell activation and apoptosis (Fig. 3-9). In patients with sepsis, the acute SIRS
phase characterized by a hyperinflammatory state and the release of pro-inflammatory
cytokines was thought to be frequently followed by an immunosuppressive CARS phase and
presence of anti-inflammatory cytokines (168). However, recent evidence suggests that both
pro- and anti-inflammatory responses occur simultaneously from the onset of sepsis with
one prevailing over the other during the course of the disease (7, 169, 170). Similarly, we
showed that both inflammatory and immunosuppressive processes are triggered
simultaneously in T cells immediately after SEA inhalation, confirming the relevance of S.
aureus enterotoxins in the pathology of sepsis.
In sum, our study demonstrated that inhaled SEA rapidly enters the bloodstream and
triggers systemic inflammation by forming an inflammatory cell network comprised of both
the innate and adaptive immune system. In particular, our findings revealed a dual
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mechanism of monocyte and neutrophil recruitment by SEA-specific T cells relying on
overlapping and non-overlapping roles of the non-inducible costimulatory receptor CD28
and the inflammatory cytokine TNF. Treatments for SIRS/sepsis may benefit by targeting
disease initiation rather than treating the consequent symptoms.
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FIGURE 3-1: After inhalation, SEA circulates systemically via blood. Tail blood was
collected 10 or 30 min after SEA or vehicle inhalation and the serum or blood cells were
incubated overnight with enriched naïve T cells. The expression of activation markers CD69
and CD25 was measured on SEA-activated CD3+Vβ3+ T cells and on bystander CD3+Vβ14+
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T cells by flow cytometry. A) Representative histograms of CD69+ and CD25+ cells in
CD3+Vβ3+ and CD3+Vβ14+ populations after a co-culture of naïve T cells with serum from
SEA or vehicle mice. B) Percent of CD69+ and CD25+ cells in CD3+Vβ3+ and CD3+Vβ14+
populations after a co-culture of naïve T cells with serum from SEA or vehicle mice. C)
Concentration of IL-2 in the supernatants from a co-culture between naïve T cells and serum
or cells from blood harvested from SEA or vehicle mice. Data were combined from 3
independent experiments with n=3 in vehicle group and n=6 in SEA group. Data are shown
as mean ± SEM. Statistical significance was determined by two-tailed Student’s t-tests
(*P<0.05; **P<0.01; ***P<0.001).

Figure 3-2: Estimation of SEA levels in serum immediately after inhalation. Naïve
enriched T cells were incubated overnight with increasing concentrations of SEA. The
percentages of CD69+ and CD25+ cells in CD3+Vβ3+ and CD3+Vβ14+ was detected by flow
cytometry. The dashed horizontal line represents the average percent of CD69+ or CD25+
cells in CD3+Vβ3+ T cells after a co-culture with serum (1:4 diluted in culture medium) from
mice 10 min after SEA inhalation (see Fig. 3-1). Data were combined from 3 independent
experiments with n=3.
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FIGURE 3-3: SEA inhalation induces systemic migration of inflammatory monocytes
and neutrophils. Peripheral blood, BM, LNs and spleen were collected after SEA or vehicle
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inhalation. A) Representative plots of cervical LN cells 4 h after SEA or vehicle challenge to
identify Lin−(CD3/CD19−)CD11b+Ly6G-Ly6Chi inflammatory monocytes and
Lin−CD11b+Ly6G+Ly6C+ neutrophils. The percent is relative to live cell gate. B) Percent of
monocytes and neutrophils in peripheral blood 2 and 4 h after SEA or vehicle challenge.
Data were combined from 3 independent experiments with n=8 per group. C) Percent of
inflammatory monocytes and neutrophils in LNs and spleen 4 and 12 h after SEA or vehicle
challenge. Non-draining LNs = axillary, brachial, inguinal, and mesenteric LNs. Data were
combined from 3 independent experiments with n=3 for vehicle group and n=6 for SEA
group. D) Absolute number of inflammatory monocytes and neutrophils in BM from one
femur and tibia 1.5 and 4 h after SEA or vehicle challenge. Data were combined from at
least 3 independent experiments with n=6-8 per group. Data are shown as mean ± SEM.
Statistical significance was determined by two-tailed Student’s t-tests (*P<0.05; **P<0.01;
***P<0.001).

FIGURE 3-4: T cells are required for the systemic recruitment of inflammatory
monocytes and neutrophils after SEA inhalation. TCR βδ−/− mice received C57BL/6J T
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cells or nothing. On the next day, they were challenged with SEA or vehicle and cervical
LNs and peripheral blood were collected 6 h after the challenge to identify
Lin−(CD3/CD19−)CD11b+Ly6G-Ly6Chi inflammatory monocytes and Lin−CD11b+Ly6G+Ly6C+
neutrophils. For cervical LNs, data were combined from at least 4 independent experiments
with n = 8-12 per group. For peripheral blood, data were combined from at least 3
independent experiments with n = 6-10 per group. Data are shown as mean ± SEM.
Statistical significance was determined by two-tailed Student’s t-tests (*P<0.05; **P<0.01;
***P<0.001).

45

FIGURE 3-5: Inflammatory innate immune cells migrate to the T cell zone of the LNs
after SEA inhalation. A) Representative confocal microscopy images of frozen sections
from cervical LNs 1, 2 and 4 h after SEA or vehicle challenge. Inflammatory innate immune
cells (monocytes and neutrophils) were labeled with anti-CD11b and anti-7/4 antibodies.
The white dashed line marks B cell follicles and was determined by anti-B220 staining (not
shown). The vertical panel on the right represents an enlarged image of the area in the
white square. The displayed images are projections of confocal z stacks taken using 20×
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magnification/0.8 numerical aperture objective and Zeiss LSM780 confocal microscope.
Scale bar = 80 µm. B) Number of 7/4+ cells. The amount of 7/4+ cells per field was
determined from 3 images per mouse by Imaris (Bitplane). Statistical significance was
assessed by two-tailed Student’s t-tests (***P<0.001). C) Position of 7/4+ cells in LNs. The
number of 7/4+ cells in B cell follicles vs. T cell zone was determined from 3 images per
mouse by Imaris. The data are representative of least 3 independent experiments with n=35 per group.
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FIGURE 3-6: SEA inhalation causes an increased expression of monocyte and
neutrophil chemotactic factors in LNs. A) Changes in chemokine gene expressions after
SEA inhalation. Draining LNs (cervical and mediastinal) were collected 1, 2 or 4 h after SEA
or vehicle inhalation and lysed to isolate RNA. qRT-PCR expression was normalized to βactin and is represented as a fold change relative to vehicle-treated group (dashed line set
as 1). Individual chemokine expressions were divided into 3 groups based on their
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expression patterns (early increase in expression:

; late increase in expression: n; late

decrease in expression: n). Data were combined from 3 independent experiments with n = 7
per group. Data are shown as mean + SEM. B) Changes in chemokine protein levels after
SEA inhalation. Draining LNs were collected 4 or 16 h after SEA or vehicle exposure. Whole
tissue was lysed with magnetic beads and chemokine expressions were measured with a
multiplex assay. Data were combined from three independent experiments with n = 6 (4 h
exposure) or n = 3 (16 h exposure). Data are shown as mean ± SEM. Statistical significance
was determined by two-tailed Student’s t-tests (*p<0.05; **p<0.01; ***p<0.001).
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FIGURE 3-7: T cells and DCs express chemokines after SEA inhalation. LNs (axillary,
brachial, inguinal, mesenteric, cervical and mediastinal) were collected 2 h after SEA or
vehicle challenge and cells were stained to sort for specific populations. RNA isolated from
the sorted populations was used for qRT-PCR analysis. A) Expression of Cxcl1, Cxcl2, Ccl3
and Ccl4 in CD3−CD19−(or B220−)NK1.1−DX5−MHC II+CD11c+ conventional DCs (cDCs). B)
Expression of Ccl3 and Ccl4 in Vβ3+ and Vβ14+ T cells. C) Gating strategy to isolate
migratory and resident DCs. D) Expression of Cxcl1 and Cxcl2 in migratory and resident
DCs. Expression of chemokines is shown relative to β-actin. Data are displayed as mean +
SEM. Data are representative of 3 independent experiments with n=3 per group. Statistical
significance was determined by two-tailed Student’s t-tests (*P<0.05; **P<0.01; ***P<0.001).

FIGURE 3-8: Migratory DCs present SEA to T cells. A) Gating strategy used to sort for
DC subpopulations. B) CD69 expression on T cells after co-culture with ex vivo derived
DCs. LNs were harvested 40 min after SEA or vehicle inhalation and the sorted DC
subpopulations were co-cultured with naïve T cells. The expression of CD69 was measured
on SEA-activated CD3+Vβ3+ T cells and on bystander CD3+Vβ14+ T cells by flow cytometry.
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Data are displayed as mean ± SEM and are representative of 4 independent experiments
with n=4 per group. Statistical significance was determined by two-tailed Student’s t-tests
(*P<0.05; **P<0.01; ***P<0.001).
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FIGURE 3-9: SEA simultaneously activates and suppresses T cells. LNs were removed
40 min after SEA or vehicle inhalation. The total RNA from the sorted Vβ3+ and Vβ14+ T
cells was used for genomic sequencing. A) Purity of Vβ3+ cells and Vβ14+ cells. The percent
is relative to live cell gate. B) Heat map of the most downregulated and upregulated genes
in SEA-activated Vβ3+ T cells compared to vehicle Vβ3+ T cells and SEA Vβ14+ T cells
(control groups). Genes that had a significantly altered expression (log2 fold change ≤ −1.5
or ≥ +1.5) in SEA-activated Vβ3+ cells compared to either vehicle Vβ3+ T cells or SEA Vβ14+
T cells in all 3 experiments were selected. C) Net enrichment score (NES) for gene ontology
clusters upregulated in SEA-activated Vβ3+ cells compared to control groups (GSEA;
*P<0.01). D) Log2 fold change in the expression of cytokines in SEA-activated Vβ3+ T cells
compared to vehicle Vβ3+ T cells. Significant difference is represented by a dashed line
(≥1.5). Data are shown as mean ± SEM. E) Heat map showing expression of inducible and
constitutively expressed costimulatory molecules in SEA Vβ3+ T cells and control groups
(vehicle Vβ3+ and SEA Vβ14+ T cells) 40 min after SEA or vehicle inhalation. F) Log2 fold
change in the expression of costimulatory molecules in SEA-activated Vβ3+ T cells
compared to vehicle Vβ3+ T cells. Significant difference is represented by a dashed line
(≥1.5). Data are displayed as mean ± SEM. G) Heat map of coinhibitory molecules in SEAactivated Vβ3+ T cells and vehicle Vβ3+ and SEA Vβ14+ control groups. H) Log2 fold change
in the expression of coinhibitory molecules in SEA Vβ3+ T cells compared to vehicle Vβ3+ T
cells. Significant difference is represented by a dashed line (≥1.5). Data are displayed as
mean ± SEM. Data are representative of 3 independent experiments with n=3 per group.
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FIGURE 3-10: Inducible costimulatory molecules 41BBL and CD40L are not involved
in the recruitment of monocytes and neutrophils after SEA inhalation. A) and B)
Percent of Lin−(CD3/CD19/NK1.1−)CD11b+Ly6G-Ly6Chi monocytes (A) and
Lin−CD11b+Ly6G+Ly6C+ neutrophils (B) in draining LNs (cervical and mediastinal) and blood
in mice treated with anti-4-1BBL or anti-CD40L prior to SEA challenge. Two hours prior to
SEA inhalation, mice were treated with anti-4-1BBL or anti-CD40L or the respective IgG
control i.p. Blood and draining LNs were removed 4 hours after the SEA challenge. Data
were combined from 2 independent experiments with n=6 per group. Data are shown as
mean ± SEM. Statistical significance was determined by two-tailed Student’s t-tests.
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FIGURE 3-11: The migration of monocytes and neutrophils after SEA inhalation is
dependent on CD28 and TNF. A) The NFκB signaling via TNF is upregulated in SEAactivated Vβ3+ T cells 40 min after SEA inhalation. GSEA was used to evaluate significantly
enriched pathways in SEA-activated Vβ3+ cells compared to the control groups (vehicle
Vβ3+ cells and SEA Vβ14+ cells). Data are representative of 3 independent experiments with
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n=3 per group. B) Concentration of serum IL-6 in mice treated with CTLA4-Ig or anti-TNF
prior to i.n. SEA challenge. Two hours prior to SEA inhalation, mice were treated with
CTLA4-Ig or anti-TNF antibody or the respective IgG control i.p. Serum was collected 4
hours after SEA challenge. C) Chemokine expressions in non-draining LNs (mesenteric,
axillary, brachial, inguinal) from mice that were treated with either CTLA4-Ig or anti-TNF and
the respective IgG control prior pulmonary SEA challenge. Tissue was collected 4 hours
after the SEA challenge. The qRT-PCR expression was normalized to β-actin and it is
expressed as a fold change relative to the IgG-treated group. D) and E) Percent of
Lin−(CD3/CD19/NK1.1−)CD11b+Ly6G-Ly6Chi monocytes (D) and Lin−CD11b+Ly6G+Ly6C+
neutrophils (E) in draining LNs (cervical and mediastinal) and blood in mice treated with
CTLA4-Ig or anti-TNF prior to SEA inhalation. Tail blood and draining LNs were collected 4
h after SEA challenge. Data were combined from 3 independent experiments with n=7-9 per
group. Data are shown as mean ± SEM. Statistical significance was determined by twotailed Student’s t-tests (*P<0.05; **P<0.01; ***P<0.001). F) and G) Correlating the percent of
D-LNs (draining LNs) neutrophils with the percent of neutrophils in blood (F) and ND-LNs
(non-draining LNs) Cxcl2 expression (G). Data are representative of 3 independent
experiments with n=9 per group. The P value of the linear regression fit curve is calculated
from F test.
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TABLE 3-1: SEA inhalation rapidly alters expression of multiple genes in Vβ3+ T cells.
Mice were challenged with SEA or vehicle and LNs were removed 40 min after the
challenge. The cells were sorted for Vβ3+ and Vβ14+ cells and the total RNA from the sorted
cells was used for transcriptome sequencing analysis. Expression of genes from SEAactivated Vβ3+ T cells was compared to the expression in vehicle Vβ3+ and SEA Vβ14+
control groups. Genes that had a significantly decreased (log2 fold change ≤ −1.5) or
increased (log2 fold change ≥ +1.5) expression in SEA-activated Vβ3+ T cells compared to
either vehicle Vβ3+ or SEA Vβ14+ T cells in all 3 experiments were selected. The table lists
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genes (symbols and names) with decreased (blue) or increased (red) expression in SEAactivated Vβ3+ cells compared to the controls. Data are representative of 3 independent
experiments with n=3 per group.

TABLE 3-2: Genes enhanced by CD28 signaling are upregulated by T cells after SEA
inhalation. The table shows genes with increased expression in SEA Vβ3+ T cells
compared to the vehicle Vβ3+ control group that were previously shown to be enhanced by
CD28 signaling (138-140). The log2 fold change is an average of log2 fold changes in SEAactivated Vβ3+ T cells vs. vehicle Vβ3+ T cells from 3 independent experiments. For some of
the genes, log2 fold change could not be calculated as the expression of these genes was
not detected in one or more of the samples in the vehicle Vβ3+ group (labeled N/A). Data
are representative of 3 independent experiments with n=3 per group.
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Chapter 4: Pulmonary Response Following S. aureus Enterotoxin A Inhalation

This work was published in the American Journal of Physiology – Lung Cellular and
Molecular Physiology, vol. 313, issue 1, pp. 177-191, July 1, 2017 under the title
“Therapeutic blockade of CD54 attenuates pulmonary barrier damage in T cell-induced
acute lung injury” and was authored by: Julia Svedova, Antoine Ménoret, Payal Mittal,
Joseph M. Ryan, James A. Buturla, and Anthony T. Vella.

Abstract

Acute respiratory distress syndrome (ARDS) is a serious, often fatal condition without
available pharmacotherapy. While the role of innate cells in ARDS has been studied
extensively, emerging evidence suggests that T cells may be involved in disease etiology.
Staphylococcus aureus enterotoxins are potent T cell mitogens capable of triggering lifethreatening shock. We demonstrate that 2 days after inhalation of S. aureus enterotoxin A,
mice developed T cell-mediated increases in vascular permeability, as well as expression of
injury markers and caspases in the lung. Pulmonary endothelial cells underwent sequential
phenotypic changes marked by rapid activation coinciding with inflammatory events
secondary to T cell priming, followed by reductions in endothelial cell number juxtaposing
simultaneous T cell expansion and cytotoxic differentiation. Although initial T cell activation
influenced the extent of lung injury, CD54 (ICAM-1) blocking antibody administered well
beyond enterotoxin exposure substantially attenuated pulmonary barrier damage. Thus,
CD54-targeted therapy may be a promising candidate for further exploration into its potential
utility in treating ARDS patients.
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Introduction

Despite decades of research, acute lung injury (ALI)/acute respiratory distress
syndrome (ARDS) remains an underdiagnosed and undertreated life-threatening condition
and accounts for over 10% of all intensive care unit admissions (87). ALI/ARDS is a
syndrome of acute lung inflammation that presents with bilateral lung infiltrates, pulmonary
edema, and hypoxemia (88). The mechanism of ALI/ARDS involves a pulmonary or
extrapulmonary insult such as pneumonia, aspiration, sepsis or major surgery, leading to a
recruitment of leukocytes and platelets, release of pro-inflammatory factors, and injury to the
endothelial and epithelial layers. Disruption of the pulmonary endothelial barrier ultimately
precipitates the characteristic pathophysiological changes of increased vascular
permeability, accumulation of protein-rich fluid, and impaired gas exchange (88, 171).
The two most frequent underlying causes are pneumonia and sepsis, with most
patients developing ALI/ARDS secondary to an established bacterial, viral or fungal infection
(88). Both Gram-positive and Gram-negative bacteria can be involved (172, 173), but
previous studies have preferentially focused on Gram-negative bacteria and, more
specifically, the effects of their bacterial-derived LPS (174). Importantly, however, there are
many cases of ALI/ARDS that are likely associated with Gram-positive bacteria, and
Staphylococcus aureus in particular, which is a major contributor to morbidity and mortality
resulting from serious infections (12, 175). One of the critical virulence factors of S. aureus
capable of inducing massive inflammation are enterotoxins (10, 176). These superantigens
bypass classical antigen presentation processes and instead induce oligoclonal expansion
of T cells by bridging MHC II with a specific T cell receptor Vβ chain (10). Superantigens are
known for their extreme potency; unlike conventional antigens activating 1/104-106 T cells,
superantigens can activate up to 1/4 T cells (22). The resultant T cell-induced inflammatory
response and cytokine storm (most notably, IL-2, IFNγ and TNF) can have disastrous
consequences leading to toxic shock, tissue damage, organ dysfunction and even death (9,
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10). Most S. aureus strains produce superantigen toxins and recent evidence suggests that
they may be involved in a number of serious illnesses, including pneumonia, sepsis, and
endocarditis (9, 16). S. aureus enterotoxin A (SEA) has been found in patients with sepsis,
and its prevalence correlated with infection severity (79, 80). In animal studies, organ
damage and lethality caused by S. aureus induced bacteremia or necrotizing pneumonia
were shown to be superantigen-dependent (85, 96, 177). Furthermore, it was demonstrated
that CD4+ T cell activation significantly exacerbated murine lung pathology and impaired
bacterial clearance in pneumonia caused by an enterotoxin-producing S. aureus strain
(178). Thus, S. aureus enterotoxins likely play a crucial role in the severity of sepsis,
pneumonia, and the associated ALI/ARDS.
Previous studies showed that administration of S. aureus enterotoxin in animal
models resulted in acute pulmonary inflammation (34, 179-181) and this response appeared
to be mediated by T cells (30, 39, 182). In particular, inhalation of S. aureus enterotoxin
firstly induced a systemic inflammatory response characterized by rapid T cell activation,
cytokine and chemokine release, and a T cell-orchestrated recruitment of innate immune
cells into the circulation, lymphoid tissues and lung (30, 34, 183, 184). This early response
occurring within several hours of S. aureus enterotoxin exposure was followed by
development of considerable lung pathology at 48 h after inhalation, which was marked by a
massive T cell expansion in lymphoid tissues and lung (34, 39). Importantly, no lung
pathology was found in the absence of T cells, in particular CD8+ T cells (39). The
pulmonary response presented with perivascular and peribronchial inflammation, disruption
of terminal vessels and accumulation of proteins, red blood cells and leukocytes in the
airways (34, 39, 105, 106). These pathological features strongly resemble the histological
findings in ALI/ARDS patients (88, 171), suggesting that S. aureus enterotoxin-activated T
cells may be capable of inducing ALI/ARDS. Although T cells were previously found to
orchestrate both the early inflammatory responses and the subsequent lung inflammation
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(30, 39, 183), the mechanism driving the development of vascular permeability is not fully
understood.
The goal of the this work was to define how SEA inhalation alters the pulmonary
barrier over time and to establish the main molecular players involved in the development of
lung injury, in order to identify clinically translatable therapeutic targets. We show that S.
aureus enterotoxin inhalation caused increased vascular permeability, elevated expression
of endothelial and epithelial injury markers, increased caspase expression in lung, and a
temporal differential cytokine/chemokine profile distinguishing intrapulmonary and systemic
responses. Mechanistically, S. aureus enterotoxin triggered rapid activation of pulmonary
endothelial cells in the early phase of inflammation, which was followed by significant
reductions in endothelial cell number during the late phase of inflammation, marked by
massive T cell expansion and cytotoxic differentiation. The early inflammatory responses
due to S. aureus enterotoxin-induced T cell activation in part determined the extent of
pulmonary barrier damage. However, remarkably, lung injury could be mitigated by
therapeutic blockade of CD54, also known as intercellular adhesion molecule-1 (ICAM-1),
when administered 36 h after initiation of inflammation. Thus, our data show that ALI/ARDS
may be treatable with immunotherapeutic agents given hours, or perhaps even days,
beyond the onset of inflammatory response.

Results

S. aureus Enterotoxin Inhalation Induces Lung Injury Marked By Cell Death
We have previously shown that upon local inhalation, SEA was detectable in serum
within minutes and triggered systemic activation of T cells. This systemic inflammatory
response was marked by cytokine and chemokine release, as well as innate cell migration
into the circulation and lymphatic tissue (183). Furthermore, activation of SEA-specific αβ T
cells induced IL-17 release by γδ T cells, which further aided recruitment of neutrophils into
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lung (30). Despite these rapid inflammatory responses occurring within the first 8 h, lung
alveolitis manifested only 2 days after SEA inhalation (39). These data suggested that in the
time period between the first minutes of systemic T cell activation and the appearance of
extensive lung histopathology at 48 h, a communication web was formed between the
systemic response and the lung mucosa, ultimately resulting in deterioration of the
pulmonary barrier function.
In line with this hypothesis, we tested for increased lung permeability and the
appearance of cellular injury markers and cell death following SEA inhalation. Lung
permeability was assessed by administering FITC-dextran, i.n. or i.v., and then measuring
fluorescence in the serum (lung-to-blood) or in the BAL fluid (blood-to-lung), respectively.
While there was no difference in permeability at 24 h in the SEA-treated mice compared to
vehicle, permeability was significantly increased by 48 h after SEA (Fig. 4-1, A). Importantly,
albumin was also increased in BAL fluid at 48 h (Fig. 4-1, B).
It was previously shown that after S. aureus enterotoxin inhalation acute alveolitis
correlated with increased T cell and innate immune cell presence in the BAL fluid and lung
(30, 34, 39, 105, 180). Here, it is shown that 48 h after SEA inhalation, clusters of SEAspecific Vβ3+ T cells were concentrated at the interstitial areas surrounding bronchioles and
perivascular regions (Fig. 4-1, C). Additionally, these specific Vβ3+ T cells co-localized with
CD11b+7/4+ inflammatory innate cells, and this area of inflammation was further
characterized by the presence of enlarged CD169+ lung macrophages (Fig. 4-1, C). The
dramatic changes in the inflammatory cell number and lung permeability suggested that
SEA inhalation could induce injury to pulmonary epithelial and endothelial cells. Indeed,
CD54, RAGE, and angiopoietin-2, which are established markers of epithelial and
endothelial cell injury in ALI/ARDS (185), were significantly increased in BAL fluid 48 h after
SEA inhalation but not at 24 h post-SEA (Fig. 4-1, D).
In a previous report, it was shown that mice lacking T cells (TCR βδ−/− mice) did not
develop any lung pathology following SEA inhalation. Furthermore, CD4-depleted WT mice
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showed a partial abrogation of the inflammatory response whereas CD8-depleted mice had
an almost complete abrogation of pulmonary inflammation (39). These findings suggested
that the inflammatory response to SEA could not occur in the absence of T cells.
Nevertheless, T cell-independent responses to a S. aureus enterotoxin have been reported
(153). Therefore, to further establish the role of T cells in SEA-induced pulmonary injury, WT
and TCR βδ−/− mice were exposed to SEA or vehicle and BAL fluid was collected 48 h after
inhalation. Unlike WT mice, SEA-exposed TCR βδ−/− mice did no show any differences in
the total number of BAL fluid cells, albumin concentration as well as the endothelial injury
marker angiopoietin-2 (186), when compared to the vehicle control (Fig. 4-2, A), confirming
the critical role of T cells in inducing lung injury after SEA inhalation.
It was next hypothesized that the increased number of inflammatory cells and the
presence of injury markers in BAL fluid were associated with apoptosis, particularly
occurring in tissues with significant T cell expansion, i.e. lung and spleen (39). To test this,
SEA- or vehicle-exposed mice received a pan-caspase-binding fluorescent probe prior to
sacrifice and the relative fluorescence levels in lung and spleen were measured. Both lung
and spleen from SEA-treated mice showed significantly greater fluorescence than control,
indicating an increase in cell death in tissues with expanded T cell population (Figs. 4-2, B
and C). To confirm that T cells were mediating the observed increase in caspase expression
in the lung and spleen, the study was repeated using TCR βδ−/− mice. No differences in
relative fluorescence between the tissues were found, demonstrating that T cells are
required for the induction of caspases in the lung (Figs. 4-2, B and C). To further validate
these findings, lung tissue sections were examined for the presence of active caspase-3, an
irreversible marker of cell death (187). Lungs from SEA-treated mice had a greater number
of active caspase-3+ cells relative to vehicle control (Fig. 4-2, D and E). Thus, SEA
inhalation caused clustering of inflammatory cells to the interstitial bronchioles and
perivascular regions, expression of epithelial and endothelial injury markers, and an
increase in cell death, ultimately giving rise to increased pulmonary permeability.
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S. aureus Enterotoxin Triggers Early And Delayed Inflammation Which Activates and
Subsequently Reduces the Number of Lung Endothelial Cells
Previous studies showed that development of pulmonary inflammation at 48 h was
preceded by a rapid systemic inflammatory response in the first several hours after S.
aureus enterotoxin inhalation. This response involved activation of enterotoxin-specific T
cells, robust cytokine and chemokine release, and a recruitment of innate immune cells into
circulation, lymphoid tissues, and lung (30, 34, 183). Our findings in Fig. 4-1, however,
suggested that there was no pulmonary injury or change in lung permeability at 24 h. In
order to better understand the relationship between the early inflammatory events and
development of lung injury at 48 h, we performed a multiplex assay on mouse serum and
BAL fluid obtained 4, 14, 24 or 48 h after SEA inhalation. As predicted, SEA induced
massive increases in serum cytokines and chemokines 4 h after inhalation (Fig. 4-3). These
levels dropped off by 14 h and were not different from the vehicle control by 24 h. In sharp
contrast, the proinflammatory cytokines/chemokines in BAL fluid were increased only at 48
h, with the exceptions of CXCL1 and IL-12p40 (Fig. 4-3). The early presence of CXCL1 and
IL-12p40 in BAL fluid could not be due to leakage from systemic circulation because, like
CXCL1 and IL12-p40, IL-6, G-CSF and CCL2 were markedly elevated in blood at 4 h, but
were not found in BAL fluid at the early time points. Therefore, we concluded that CXCL1
and IL-12p40 were likely produced locally rather than permeated from blood to BAL fluid.
This finding was consistent with our previous report showing that IL-17 release by
pulmonary γδ T cells promotes recruitment of neutrophils to the lung by 8 h after SEA
inhalation (30).
To further study pulmonary response diversity prior to the onset of injury, lung cells
were obtained from mice 14 or 40 h after SEA or vehicle inhalation, barcoded, stained with
heavy metal-conjugated antibodies and analyzed by cytometry by time-of-flight (CyTOF),
also known as mass cytometry. The high-dimensional cytometry data were visualized as
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colorimetric 2-dimensional ViSNE maps (188), which cluster single-cell data based on
similarity in marker expression patterns. Furthermore, because the individual samples were
barcoded, pooled, and acquired simultaneously by CyTOF, each map represents all four
samples (14 h vehicle, 14 h SEA, 40 h vehicle, 40 h SEA). Using combinations of lineage
markers, we identified various lung cell populations to discern which cells were stimulated
after SEA inhalation (Fig. 4-4). We first looked at SEA-specific Vβ3+ T cells; however,
insufficient numbers of specific T cells could be collected at 14 h, likely due to activationinduced increased adherence to the tissue (189). Nevertheless, CD8+Vβ3+ and CD4+Vβ3+ T
cells (Fig. 4-5, A) isolated 40 h after SEA inhalation showed upregulation of pSTAT5 and
DNA content (Fig. 4-5, B), consistent with activation and proliferation. Interestingly, even
non-responding bystander CD4+Vβ14+ T cells showed some increase in STAT
phosphorylation (Figs. 4-5, A and B) but not to the extent of SEA-specific T cells. These
findings confirmed that CyTOF could be used to identify changes in cell signaling.
CD11c+MHC II+ dendritic cells (Fig. 4-5, C) were slightly activated at 14 h but more robustly
at 40 h as indicated by increased pSTAT3 (Fig. 4-5, D). Notably, CD45−CD31+CD54+
endothelial cells (Fig. 4-5, E) had upregulated pSTAT1 and MHC II and some
downregulation of IκB as early as 14 h after SEA inhalation (Fig. 4-5, F). These results were
replicated in 3 additional independent experiments (Fig. 4-5, G-I). Finally, STAT
phosphorylation in other lung cell populations trended with their lineages (Fig. 4-5, J and K).
Overall, these data suggest that endothelial cells became activated early but were able to
maintain their function as there were no changes in pulmonary permeability or injury
markers at 24 h (Fig. 4-1).
To study endothelial cell activation, lung cells were collected 14, 24 or 40 h after SEA
or vehicle inhalation, sorted for CD45−CD31+CD54+ endothelial cells and then analyzed for
gene expression. Sorted cells displayed a number of dynamic changes in response to SEA
(Fig. 4-6, A). Expression of integrin Vcam1 were increased at 14 h (Fig. 4-6, A), likely
signifying early activation. Interestingly, the expression of Nos3 (endothelial nitric oxide
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synthase), an enzyme essential to endothelial cell homeostasis (190, 191) was firstly
upregulated at 24 h and then downregulated at 40 h (Fig. 4-6, A). Finally, Icam1 (CD54)
expression was increased two-fold over vehicle at 40 h post-SEA inhalation (Fig. 4-6, A). In
addition to these sequential phenotype changes in pulmonary endothelial cells, there was a
significant reduction in their numbers at 48 h after SEA (Fig. 4-6, B), and endothelial cell
percentage inversely correlated with percentage of SEA-specific Vβ3+ T cells in the lung
(Fig. 4-6, C). Endothelial cells from SEA-exposed mice also showed increased CD54 and
CD95 (Fas) expressions (Fig. 4-6, D), and similarly, SEA-specific Vβ3+ T cells had greater
expression levels of CD11a (receptor for CD54) and CD95 (Fig. 4-6, E). Granzyme B was
also measured since it was found to increase in cases of septic ALI/ARDS patients (192).
Indeed, SEA-specific Vβ3+ T cells were found to have upregulated granzyme B expression
(Fig. 4-6, E), but, most importantly, robust levels of granzyme B were detected in BAL fluid
at 48 h (Fig. 4-6, F). Thus, as lung permeability manifested at time points beyond 24 h (Fig.
4-1, A), there were coincident increases in markers of cytotoxicity and cell death, particularly
granzyme B and CD95.

S. aureus Enterotoxin-Induced Lung Injury Is Dependent on T Cell Costimulation, But
Therapy Is Possible Through CD54 Interference
It was previously demonstrated that systemic recruitment of neutrophils and
monocytes after S. aureus enterotoxin-induced T cell activation was uniquely regulated by
TNF and CD28 costimulation (183). Thus, it was hypothesized that preventing early
inflammation with CD28 or TNF blockade would minimize the increase in pulmonary
permeability. Mice were pre-treated with the CD28 signaling inhibitor CTLA4-Ig, anti-TNF
antibody or IgG control 2 h prior to SEA inhalation and at 48 h post-SEA BAL fluid and lung
were harvested (Fig. 4-7, A). CTLA4-Ig and anti-TNF pre-treatment significantly reduced
BAL fluid cell numbers (Fig. 4-7, B), whereas CTLA4-Ig, but not anti-TNF, decreased the
overall proportion of T cells and inflammatory innate cells in the BAL fluid (Fig. 4-7, C;
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p=0.043 for CTLA4-Ig and p=0.12 for anti-TNF). Importantly, anti-TNF and CTLA4-Ig
significantly reduced the presence of albumin and some of the injury and inflammation
markers, but CTLA4-Ig was more potent overall at attenuating the lung injury (Fig. 4-7, D).
Additionally, CTLA4-Ig decreased the total number of monocytes in lung (Fig. 4-7, E). Thus,
early inflammatory responses define in part the severity of S. aureus enterotoxin-mediated
lung injury.
Despite the role played by early inflammatory responses in influencing the extent of
lung injury, therapeutic strategies to block them have limited translational relevance when
taking into consideration the typical disease progression and time scales involved, as well
as the logistics of diagnosing and treating patients in the hospital. Alternatively, we
investigated later events in the SEA-induced response, during which time entry and
accumulation of lung T cells is evident. Pulmonary tissue and endothelial cells in particular,
can be injured in a number of ways, including mechanisms involving cytokines and direct
death pathways such as CD95 signaling (191, 193, 194). Additionally, CD54 was previously
shown to enhance leukocyte transmigration and promote cytotoxic T cell function (195-197).
Thus, CD95 and CD54 (Fig. 4-6, D) could be essential mediators of pulmonary barrier
damage occurring later in the SEA response progression.
We therefore hypothesized that CD95 and/or CD54 blockade would prevent
pulmonary barrier leakiness at clinically relevant time points beyond the initiation of
inflammation. Thus, 36 h after SEA inhalation mice were treated with anti-CD178 (ligand for
CD95; FasL), anti-CD54 or IgG control, and BAL fluid and lung were collected at 48 h (Fig.
4-8, A). While anti-CD178 showed no change in total cell number, anti-CD54 significantly
reduced the total number of cells in BAL fluid (Fig. 4-8, B) and also decreased the overall
proportion of T cells and inflammatory innate cells present (p=0.0012, Fig. 4-8, C).
Importantly, anti-CD54 therapy potently decreased the measured injury markers (CD54 and
RAGE), inflammatory markers (granzyme B, IFNγ and IL-6), and albumin in BAL fluid (Fig.
4-8, D). Paradoxically, BAL fluid TNF levels were increased with anti-CD54 treatment (Fig.
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4-8, D). This overall reduction in inflammation was not limited to soluble factors, since CD54
blockade also reduced the total numbers of SEA-specific Vβ3+ T cells lung (Fig. 4-8, E).
Interestingly, anti-CD178 treatment only increased the number of neutrophils in the lung
while having no effect on measures of lung injury (Fig. 4-8, D and E). To validate the effect
of anti-CD54 on preserving lung barrier integrity, mice were treated with anti-CD54 or IgG
control 36 h after SEA inhalation, and lung permeability was measured with FITC-dextran
(as described previously) at 48 h. Indeed, the anti-CD54-treated mice showed significantly
lower levels of FITC fluorescence in BAL fluid relative to IgG-treated mice, but not
statistically different from vehicle control (p=0.27; Fig. 4-8, F). While CD54 blockade reduced
total numbers of SEA-specific T cells in the lung by 45% (Fig. 4-8, E), we also observed
substantial decreases in BAL fluid IFNγ and granzyme B levels (73% and 76%, respectively)
in the treated mice (Fig. 4-8, D). These findings suggest that anti-CD54 therapy might
directly diminish T cell cytotoxic potential, in addition to reducing pulmonary T cell infiltration.
However, there was no difference in IFNγ and granzyme B expressions by SEA-specific
CD8+ T cells (Fig. 4-8, G), suggesting that the synthesis of cytotoxic molecules was not
markedly impacted by the therapy. In sum, these findings demonstrate that anti-CD54
therapy significantly attenuates S. aureus enterotoxin-mediated lung injury well after the
initiation of inflammation.

Discussion

ALI/ARDS is a life-threatening condition that affects approximately 200,000 people in
the United States annually, but despite recent advances in supportive care, the mortality
rates remain unacceptably high (87, 88, 171). Although many clinical studies investigated
various pharmacotherapies for ALI/ARDS, results have been mostly disappointing (8, 171).
Thus, there is an urgent need to better understand the mechanisms of tissue injury in order
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to design novel treatments for ALI/ARDS, and we propose CD54 as a promising
immunotherapeutic target.
While the role of innate cells, particularly neutrophils and macrophages, has been
studied extensively in ALI/ARDS (129, 198), the involvement of adaptive immunity, T cells,
in particular, is only now beginning to emerge (90). Prior studies showed that ALI/ARDS
patients present with greater numbers of lymphocytes in circulation (91) and in BAL fluid
(92). Furthermore, the T cell growth factor IL-2 was found to be elevated in BAL fluid of
ARDS patients and was strongly associated with increased mortality (93, 94). ARDS
alveolar T cells also showed significant increases in activation, proliferation, and cytokine
secretion (199). In mouse models of ALI, Th17 cells were shown to be pathogenic (92),
while Tregs were essential for recovery (200). Nevertheless, the mechanism of T cell-based
pulmonary injury is unclear. Similar to LPS and bleomycin inhalation in mice (201), SEA
models acute lung injury but with greater emphasis on the role of T cells. It is important to
note that enterotoxins, including SEA, have been detected in the circulation of intensive care
unit patients (79), and also in S. aureus isolates from individuals with complications from
pneumonia (177, 202). This only suggests an association of S. aureus enterotoxins with
ARDS, but non-human primates exposed to aerosolized enterotoxin exhibited severe
pulmonary lesions with lethality in some subjects (98). Thus, there is a critical need to
attempt to identify S. aureus enterotoxin protein in BAL fluid of ALI/ARDS patients.
To explore the mechanisms governing the development of ALI following S. aureus
enterotoxin inhalation, we first defined the inflammatory changes that take place in the lung
in terms of two distinct phases. The initial response is caused by rapid, oligoclonal T cell
activation leading to robust cytokine and chemokine release (Fig. 4-3), and recruitment of
neutrophils and monocytes into circulation followed by their appearance in the lung (30,
183). This phase of the response occurs within hours after SEA inhalation. Here we found
that the early inflammatory responses were accompanied by changes in cell signaling and
the appearance of activation markers of endothelial cells. Upregulation of pSTAT1 and MHC
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II (potentially in response to IFNγ stimulation (203, 204)) and changes in mRNA expression
levels of integrin Vcam1 was evident (Figs. 4-5, F and 4-6, A). However, there were no
changes in lung permeability or signs of damage noted (Fig. 4-1) and the barrier was also
impermeable even to the high levels of circulating cytokines found in the serum at 4 h (Fig.
4-3).
Lung permeability was clearly increased at 48 h (Fig. 4-1, A), which coincides with
the second phase of the inflammatory response marked by robust T cell expansion in the
lung (39). This occurs just prior to peripheral T cell deletion and anergy, which is a noted
outcome of enterotoxin T cell response (43, 44). The change in lung permeability was
further accompanied by increased levels of soluble CD54, angiopoietin-2 and RAGE (Fig. 41, D), increased expression of caspases (Fig. 4-2) and elevated cytokines and chemokines
in BAL fluid (Fig. 4-3). At 40 h after SEA inhalation, the onset of the second phase was
marked by changes in signaling events and activation of different pulmonary cell populations
(Fig. 4-5). In particular, pSTAT5 expression was increased in T cells and NK cells (Fig. 4-5,
G and J), whereas pSTAT3 expression was increased in dendritic cells and alveolar
macrophages (Fig. 4-5, H and K). We posit that STAT5 phosphorylation is in response to T
cell release of IL-2, while IL-6 release from innate cells promotes STAT3 phosphorylation
(203). On the other hand, endothelial cells upregulated Icam-1 and downregulated Nos3
transcription (Fig. 4-6, A), suggesting a loss of homeostatic mechanisms and polarization
toward a more activated phenotype (190, 205). Finally, this later effect likely portended the
reduction of endothelial cells, which also coincided with increased CD54 and CD95
expression (Figs. 2-6, B and D). Thus, lung endothelial cells became activated and later
began to disappear, probably by a death process, as S. aureus enterotoxin induced T cell
activation and expansion.
Taken together, these findings suggested a two-hit mechanism of endothelial cell
injury: firstly, pulmonary endothelial cells became activated (Figs. 4-5, F and 4-6, A) due to
early inflammatory responses occurring systemically or locally, but the endothelial barrier
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remained intact throughout this phase (Fig. 4-1). More specifically, the massive levels of
serum cytokines detected at 4 h (Fig. 4-3) or the transiently recruited neutrophils in the lung
(30) could activate the endothelial cells without invoking their injury or death. A second hit,
coinciding with the systemic and intrapulmonary expansion of SEA-specific T cells, induced
the endothelial cells to downregulate homeostatic factors and acquire a more activated and
death-prone phenotype, eventually leading to cellular dysfunction and death. Recently, it
was proposed that sequential hits to the lung from various insults, such as pneumonia,
sepsis, or mechanical ventilation may cause the severe pathology of ARDS. This proposed
model for disease etiology and progression is known as the “multiple hit theory” (8).
Similarly, animal models of ALI that consist of two inflammatory insults to the lung may
better mimic the clinical scenario (206).
To unravel the mechanism responsible for the observed increase in pulmonary
permeability, we designed our experimental strategy based on recent data showing that the
early inflammatory responses were differentially affected by blocking TNF or CD28
costimulation (183). In the current report, we demonstrate that TNF or CD28 blockade
elicited a profound reduction of albumin in BAL fluid as well as diminished inflammation and
expression of injury markers in the lung (Fig. 4-7). Thus, although there were no changes in
pulmonary permeability initially (Fig. 4-1), early blockade of T cell activation reduced the
subsequent lung injury. Consistent with the two-hit injury model, these findings suggested
that the activation of endothelial cells due to an initial inflammatory stimulus may not
necessarily induce their injury and death but may increase their sensitivity to secondary
injury.
Understanding that the initial T cell activation influences lung injury at later time
points is undoubtedly important; however, it may be difficult to translate these findings into
clinical care, since delivering early therapy during the initial insult is often not possible.
Previous studies attempting to reduce the inflammatory response after S. aureus enterotoxin
inhalation administered therapy prophylactically or immediately after toxin exposure (207-
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210). Alternatively, we sought a therapeutic approach to reduce S. aureus enterotoxininduced lung injury in a scenario mimicking a clinical setting wherein enterotoxin inhalation
preceded initiation of therapy by many hours. Because CD95 and CD54 were upregulated
on endothelial cells after SEA inhalation (Fig. 4-6, D), we administered blocking antibodies
targeting CD178 and CD54 at 36 h post-SEA. Previous studies found that both CD95 and
CD178 were elevated in BAL fluid of ALI/ARDS, and the CD95/CD178 pathway may be
critical for inducing epithelial cell injury (86, 192, 211, 212). However, with the exception of
increasing lung neutrophil numbers (Fig. 4-8, E), blocking CD178 had no effect on lung
injury measures in our model (Fig. 4-8, B-D). In sharp contrast, CD54 blockade profoundly
reduced pulmonary injury, by means of decreasing BAL fluid cell number, preventing
increases in proinflammatory cytokine release, minimizing expression of markers of
endothelial and epithelial cell damage, and reducing lung permeability (Fig. 4-8). Being a
costimulatory molecule, CD54 is expected to inhibit T cell activation at the time of antigen
presentation (213-216), but our results show that many hours after SEA-induced activation,
CD54 plays an active role in shaping T cell responses. In particular, specific T cell numbers
were significantly reduced after CD54 therapy (Fig. 4-8, E). In addition to reducing T cell
expansion in lung, another proposed mechanism by which CD54 blockade might maintain
the lung barrier is based on data showing that CD54 was important for enhancing cytotoxic
function of lymphocytes (194, 217, 218). Similarly, we observed substantial reductions in
granzyme B and IFNγ in the BAL fluid of anti-CD54-treated mice (Fig 2-8, D). Intriguingly,
there was no difference in the cytotoxic potential of SEA-specific CD8+ T cells after CD54
therapy (Fig. 4-8, G), suggesting effector T cell differentiation was not markedly impaired.
Rather than the synthesis, anti-CD54 therapy could be involved in regulating the release of
cytotoxic and inflammatory molecules (196). Finally, although SEA-induced lung injury is T
cell-dependent (Fig. 4-2), other cell populations, including inflammatory innate cells are
recruited to lung (Fig. 4-1, C). Therefore, anti-CD54 could also ameliorate the SEA-induced
lung injury by affecting other cell types, such as neutrophils and monocytes. Although
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recruitment of neutrophils and monocytes to lung was no affected by anti-CD54 (Fig. 4-2, E),
the treatment could affect the function of these cells, such as reactive oxygen species
production (219). CD54-targeted therapy was previously shown to attenuate pulmonary
damage in two models of neutrophil-dependent lung injury (220, 221) and anti-CD54
antibody (enlimomab) has already been tested in several clinical trials (e.g. transplantation,
burn injuries and refractory rheumatoid arthritis) (222-224). Therefore, anti-CD54 may be a
potential therapeutic target for ALI/ARDS worthy of further investigation. Finally, taking into
account the role of CD54 in leukocyte migration during injury or infection (197), it will be
important to accurately define therapeutic windows for CD54-blocking therapies given to
ALI/ARDS patients. Furthermore, determining the molecular players downstream of CD54
engagement may also enable development of more targeted treatment options.
The utility of CD54 therapy is well matched to a typical ALI clinical scenario. A patient
suffering from a severe pneumonia or trauma may experience over-activation of the immune
system and/or direct damage to the tissue, resulting in impaired lung barrier defenses. This
deficit may predispose the patient to additional insults such as toxins and danger- and
pathogen-associated molecular patterns that can give rise to systemic inflammatory
response syndrome and/or ALI with T cells likely playing a crucial role (225). An excellent
example is the appreciation of S. aureus enterotoxins in septic patients (79-81). Here, S.
aureus enterotoxin inhalation was found to induce sequential changes in the lung, defined
by initial rapid endothelial cell activation coinciding with inflammatory responses due to T
cell priming followed by pulmonary injury and cell death coinciding with T cell expansion in
the lung. Importantly, even when administered therapeutically at time points well beyond the
inciting inflammatory trigger, anti-CD54 effectively reduced all measures of lung
inflammation and injury and restored pulmonary barrier integrity. Thus, an
immunotherapeutic agent targeting CD54 pathway may be a suitable treatment option for
ALI/ARDS patients, especially in suspected cases of T cell-induced inflammation.
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FIGURE 4-1: SEA increases pulmonary permeability, cellular recruitment and
expression of epithelial and endothelial markers of injury 2 days after inhalation. A)
Permeability in the lung was measured by FITC-dextran fluorescence assay. In the left
panel, FITC-dextran was administered i.n. and serum was obtained 1 h later (24 and 48 h
after SEA or vehicle inhalation). FITC fluorescence was measured in serum and normalized
to the vehicle control. At least 3 independent experiments with n=8-11 per group. In the right
panel, FITC-dextran was administered i.v. and BAL fluid was obtained 1 h later (48 h after
SEA or vehicle). FITC fluorescence was measured in BAL fluid and normalized to vehicle
control. Two independent experiments with n=6-10 per group. B) Concentration of albumin
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in BAL fluid 24 and 48 h after SEA or vehicle inhalation. Three independent experiments
with n=5 per group. C) Representative confocal microscopy images of lung tissue showing
clusters of recruited myeloid cells (CD11b+ 7/4+) and SEA-specific T cells (Vβ3+) in proximity
to macrophages (CD169+) 48 h after SEA inhalation. B = bronchiole, V = blood vessel. Scale
bar = 80 µm. Images are representative of 3 independent experiments with n=4 for vehicle
and n=6 for SEA. D) Concentration of the lung injury markers CD54, angiopoietin-2 and
RAGE in BAL fluid 24 and 48 h after SEA or vehicle inhalation. Three experiments with n=58 per group. Data are shown as mean ± SEM. Two-way ANOVA with Sidak’s test or
unpaired t test ( for Fig. 1A, right panel); **p<0.01, ***p<0.001.
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FIGURE 4-2: SEA induces apoptosis in the lung in a T cell-dependent manner. A)
Number of BAL fluid cells and the concentration of albumin and angiopoietin-2 (ang-2) in
BAL fluid 48 h after SEA or vehicle inhalation in WT and TCR βδ−/− mice. Two independent
experiments with total n=6 per group. B) Apoptosis in the lung and spleen of WT and TCR
βδ−/− mice 54 h after SEA or vehicle inhalation as measured by a pan-caspase-binding
fluorescent probe. After injecting the probe i.v., tissue was removed and scanned by a
fluorescence imager. C) Quantification of the pan-caspase-binding fluorescent probe in the
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lung and spleen of WT and TCR βδ−/− mice 54 h after SEA or vehicle inhalation. Three
independent experiments with n=8-18 mice per group. D) Representative confocal
microscopy images of lung tissue showing the presence of apoptotic cells (active caspase3+) 48 h after SEA inhalation. Scale bar = 80 µm. The right panels depict magnified images
of the fields indicated in the left panels. E) Number of active caspase-3+ cells per field. The
number of positive cells 48 h after SEA or vehicle inhalation was determined from 3 images
per mouse using Imaris (Bitplane). Counts in the SEA mice were performed in areas of
inflammation. Data are representative of 3 independent experiments with n=4 for vehicle
and n=6 for SEA. Data are shown as mean ± SEM. Two-way ANOVA with Sidak’s test or
unpaired t test (for Fig. 2E); ***p<0.001.
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FIGURE 4-3: There are differential patterns of cytokine and chemokine release in BAL
fluid vs. serum after SEA inhalation. BAL fluid and serum were collected 4, 14, 24 and 48
h after SEA or vehicle inhalation, and protein levels of various analytes were measured by
multiplex immunoassay. Data were combined from 3 independent experiments with n=4-7
per group. Data are shown as mean ± SEM. Two-way ANOVA with Sidak’s test; **p<0.01,
***p<0.001.
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FIGURE 4-4: Gating strategy to identify lung cell populations using ViSNE maps.
Lungs were obtained from mice 14 or 40 h after SEA or vehicle inhalation. Each sample was
barcoded, stained with heavy metal-conjugated antibodies and analyzed by mass cytometry
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(Helios, Fluidigm). Data were debarcoded, and samples were further subgated to include
33,000 cells and merged to generated the ViSNE maps (Matlab). The VisNE maps identify
clusters of cells that are generated according to marker expression patterns. Expression of
each marker can be quantified based on the color gradient indicated on the left. The
individual clusters in boxes in the periphery of figure 4 are phenotyped with known lineage
markers and expression of the underlined marker is shown. The identity of each cluster is
indicated in bold letters. Images are representative of 4 independent experiments.
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FIGURE 4-5: Endothelial cells become activated prior to the appearance of lung
pathology. Lung tissue was obtained from mice 14 or 40 h after SEA or vehicle inhalation.
Individual samples were barcoded, pooled and then stained with heavy metal-conjugated
antibodies. The pooled sample was analyzed by mass cytometry (Helios, Fluidigm). ViSNE
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maps generated using MATLAB were used to represent clusters of cells identified according
to expression of markers used in the experiment. Expression of each marker can be
visualized based on the color gradient indicated on the left. A) ViSNE maps to identify CD3+
cells and subpopulations of CD3+ cells (SEA-specific CD45+CD3+CD8+Vβ3+ and
CD45+CD3+CD4+Vβ3+ T cells and bystander CD45+CD3+CD4+Vβ14+ T cells). B) Histograms
showing the expression of signaling and activation markers in T cells 40 h after vehicle
(blue) vs. SEA (red) inhalation. C) ViSNE maps identifying dendritic cells
(CD45+CD11c+MHC II+). D) Histograms showing the expression of signaling and activation
markers in dendritic cells 14 (top panel) or 40 h (bottom panel) after vehicle (blue) vs. SEA
(red) inhalation. E) ViSNE maps identifying endothelial cells (CD45−CD31+CD54+). F)
Histograms showing the expression of signaling and activation markers in endothelial cells
14 (top panel) or 40 h (bottom panel) after vehicle (blue) vs. SEA (red) inhalation. G) pSTAT
median intensity (MI) in T cell populations 40 h after SEA or vehicle inhalation. H) pSTAT3
median intensity in dendritic cells 14 or 40 h after SEA or vehicle inhalation. I) MHC II
median intensity in endothelial cells 14 or 40 h after SEA or vehicle inhalation. J) pSTAT5
median intensity in CD45+NK1.1+CD3− NK cells 40 h after SEA or vehicle inhalation. K)
pSTAT3 median intensity in CD45+CD11c+SIGLEC F+ alveolar macrophages 40 h after SEA
or vehicle inhalation. Each experiment is represented as a pair of connected symbols (blue
square = vehicle; red square = SEA) with a mean shown as a horizontal line. Data are
representative of 4 independent experiments with n=4 per group. Paired t test; *p<0.05,
**p<0.01.
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FIGURE 4-6: SEA inhalation causes both early and late changes in endothelial cells.
A) Endothelial cell gene expression 14, 24, or 40 h after vehicle or SEA inhalation.
Endothelial cells (CD45−CD31+CD54+) were then sorted from total lung cells and lysed to
obtain RNA. Gene expression levels are normalized to Gapdh and shown relative to vehicle
control (set to 1). Three independent experiments with n=6 per group. B) Number of lung
endothelial cells (ECs; CD45−CD31+) 48 h after SEA or vehicle inhalation as measured by
flow cytometry. C) Correlation between endothelial cell and CD3+Vβ3+ T cell percentages in
the lung 48 h after SEA inhalation. Linear regression curve fit p value was calculated via F
test. Two independent experiments with n=8 per group. D) Expression of surface CD54 and
CD95 on endothelial cells (CD45−CD31+) 48 h after SEA or vehicle inhalation. E) Surface
expression of CD11a and CD95 and intracellular expression of granzyme B (Gzm B) in
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CD3+Vβ3+ T cells 48 h after SEA or vehicle inhalation. Histograms are representative of 2
independent experiments with n=8 per group. Median fluorescent intensities in the upper
corner of each histogram are shown as average ± SD of 1 out of the 2 experiments. Isotype
control (gray), vehicle = V (black dashed line), SEA = S (black thick line). F) Granzyme B
concentration in BAL fluid of SEA or vehicle-treated mice 24 and 48 h after inhalation. Three
independent experiments with n=8 per group. Data are represented as mean ± SEM. Twoway ANOVA with Sidak’s test or unpaired t test (for Fig. 5B); *p<0.05, **p<0.01, ***p<0.001.
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FIGURE 4-7: Blocking T cell activation with CTLA4-Ig or anti-TNF in part attenuates
measures of lung permeability, cell injury and inflammation after SEA inhalation. A)
Diagram of experimental set-up. Mice were treated with CTLA4-Ig, anti-TNF or IgG control 2
h prior to SEA inhalation. BAL fluid and lung tissue were obtained 48 h after SEA inhalation.
B) Total number of BAL fluid cells pre-treated with IgG control, CTLA4-Ig, or anti-TNF as
described in “A”. C) Composition of cells within the BAL fluid following IgG control, CTLA4Ig, or anti-TNF pre-treatment. Average percentages of CD45+CD3+Vβ3− T cells,
CD45+CD3+Vβ3+ T cells, neutrophils (CD45+CD11b+Ly6C+Ly6G+) and monocytes
(CD45+CD11b+Ly6C+Ly6G−) in BAL fluid are represented by stacked bars. D)
Concentrations of injury markers angiopoietin-2 (ang-2), RAGE, CD54), inflammatory
markers granzyme B (gzm B), IFNγ, IL-6, and TNF, and albumin in BAL fluid from mice pretreated with IgG control, CTLA4-Ig, or anti-TNF. E) Total number of Vβ3+ T cells, monocytes
and neutrophils in lung in mice pre-treated with IgG control, CTLA4-Ig, or anti-TNF. Data are
represented as mean ± SEM. Three independent experiments with n=9 per group. One-way
ANOVA with Dunnett’s test; *p<0.05, **p<0.01, ***p<0.001.
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FIGURE 4-8: Delayed CD54 blockade substantially minimizes lung permeability, cell
injury and inflammation after SEA inhalation. A) Diagram of experimental set-up. Mice
were administered SEA i.n., then they were treated with IgG control, anti-CD178 or antiCD54 i.p 36 h later. BAL fluid and tissue were obtained 48 h after SEA inhalation. B) Total
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number of BAL fluid cells from mice treated with IgG control, anti-CD178, or anti-CD54 as
described in “A”. C) Composition of cells within the BAL fluid following IgG control, antiCD178, or anti-CD54 treatment. Average percentages of CD45+CD3+Vβ3− T cells,
CD45+CD3+Vβ3+ T cells, neutrophils (CD45+CD11b+Ly6C+Ly6G+) and monocytes
(CD45+CD11b+Ly6C+Ly6G−) in BAL fluid are represented by stacked bars. D)
Concentrations of injury markers angiopoietin-2 (ang-2), RAGE, and CD54, inflammatory
markers granzyme B (gzm B), IFNγ, IL-6, and TNF, and albumin in BAL fluid from mice
treated with IgG control, anti-CD178, or anti-CD54. E) Total number of Vβ3+ T cells,
monocytes and neutrophils in lung in mice treated with IgG control, anti-CD178, or antiCD54. Three independent experiments with n=9 per group. F) Lung permeability measured
by FITC-dextran permeability assay. Mice were given SEA or vehicle i.n. and the SEAexposed mice were treated with IgG control or anti-CD54 36 h later. FITC-dextran was
administered i.v. 1 h prior to sacrifice. FITC fluorescence was measured in BAL fluid and
normalized to IgG-treated mice. Data were combined from 3 independent experiments with
n=7-11. G) The expression (median fluorescent intensity = MFI) of granzyme B and IFNγ in
CD8+Vβ3+ T cells (CD45+CD3+CD8+Vβ3+). The lung cells were cultured with brefeldin A only
(granzyme B) or brefeldin A + PMA/ionomycin (IFNγ) for 5 h and stained with antibodies.
Two independent experiments with total n=6-8 per group. Data are shown as mean ± SEM.
One-way ANOVA with Dunnett’s test (for Fig. 4-8, B-E) or One-way ANOVA with Tukey’s
test (for Fig. 4-8, F and G); *p<0.05, **p<0.01, ***p<0.001.
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Chapter 5: Alveolar Macrophages in S. aureus Enterotoxin A-Mediated
Inflammation

The findings of this chapter were published in ImmunoHorizons, vol. 1, issue 9, pp. 213-222,
November 1, 2017 under the title “CD169+ macrophages restrain systemic inflammation
induced by Staphyloccocus aureus enterotoxin A lung response.” The article was written by
Julia Svedova, Antoine Ménoret, Stephen T. Yeung, Masato Tanaka, Kamal M. Khanna,
and Anthony T. Vella.

Abstract
Alveolar macrophages (AMs) are considered the first line of defense in the airways.
Exposure to harmful substances and certain infections can lead to dysfunction or depletion
of AMs. Importantly, these conditions have been associated with increased risk of sepsis
and acute lung injury. Staphylococcus aureus enterotoxins are superantigens that induce
oligoclonal activation of T cells and a robust cytokine release, leading to systemic
inflammatory response and tissue injury. This study investigated the relationship between S.
aureus enterotoxins and AMs. Following inhalation, S. aureus enterotoxin was preferentially
bound to AMs and the binding was independent of MHC II. Furthermore, the enterotoxin
was internalized and its presence in the cells decreased by 24 h after exposure. Ablation of
AMs in CD169-DTR mice was associated with increased activation of enterotoxin-specific T
cells and enhanced cytokine release into circulation. Thus, conditions causing depletion of
AMs may increase the risk of S. aureus enterotoxin-induced diseases.

Introduction
Alveolar macrophages (AMs) are specialized tissue-resident cells that play a crucial
role in lung development, homeostasis, and immune surveillance. Their unique position in
the lung alveoli enables them to sample pathogens, inhaled particulates and other
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environmental cues. Their reciprocal interactions with neighboring cells through various
receptors and cytokine/chemokine axis can then alarm the immune system and orchestrate
responses to remove potential threats and respond to tissue injury, making them the first
line of pulmonary immune defense (226, 227). AMs have been shown to play a critical antiinflammatory role in a number of disease animal models, including influenza, asthma, and
acute lung injury (228-233) but they could be also pro-inflammatory (234, 235).
AMs are a relatively stable population of cells with very slow turnover rate; however,
if the injury is severe enough, AMs may be depleted and later replenished from circulating
monocytes or from in situ proliferation (226, 227). Exposure to various substances,
pathogens and their products may lead to AM depletion or impaired function; these include
influenza (236), bacterial pneumonia (237) cigarette smoke (238), anesthesia (239),
diabetes (240), or alcohol consumption (241). Importantly, many of these conditions or
exposures have been associated with increased risk of serious infections and development
of systemic inflammatory response syndrome (SIRS)/sepsis and acute respiratory distress
syndrome (ARDS). In particular, influenza can be complicated by a secondary bacterial
pneumonia, which leads to higher rates of hospitalization and death (242). Increased alcohol
consumption and cigarette smoke exposure have been associated with increased risk of
SIRS/septic shock and ARDS, respectively (243-246). Finally, a number of chronic
conditions, particularly diabetes mellitus, and immunosuppressive state are well-described
comorbidities in sepsis patients (7, 72, 247). Altogether, these studies suggest that depletion
or impaired function of AMs may be associated with increased risk of serious infection,
sepsis and ARDS.
Staphylococcus aureus enterotoxins are a group of potent bacterial toxins that
bypass the classical antigen processing and presentation, directly bind to MHC II on
antigen-presenting cells and crosslink it with specific Vβ chains of T cell receptors. This
unique feature of the so-called superantigens induces a massive inflammatory response
marked by oligoclonal T cell activation and cytokine storm (10, 111). Superantigens have
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been established as the mediators of toxic shock syndrome, a type of systemic inflammatory
response, which can lead to tissue injury, shock and even death (9, 36). However, recent
evidence suggest that they may be involved in a number of diseases, including pneumonia,
endocarditis, and sepsis (9, 85, 96, 177). In fact, superantigens and superantigenexpressing S. aureus strains have been recovered from septic patients (79-81). S. aureus
enterotoxins likely spread systemically from focal sites of infection rather than being directly
produced in the bloodstream, as hemoglobin peptides were shown to inhibit superantigen
production (9, 99, 100). The most common colonization site of S. aureus is the anterior
nares (11); therefore, exposure to aerosolized or inhaled S. aureus enterotoxin may well
mimic the route of dissemination. Accidental exposure to aerosolized S. aureus enterotoxin
in humans was reported to cause systemic symptoms of fever, chills, headache, myalgia,
cough, dyspnea, vomiting and diarrhea in humans (104). In non-human primates,
aerosolized lethal doses of S. aureus enterotoxin caused severe pulmonary lesions and
death in some subjects (98). Finally, S. aureus enterotoxin inhalation in mice was shown to
cause systemic inflammatory response, involving rapid activation of T cells, cytokine
release, recruitment of innate cells and subsequent lung injury (34, 39, 183).
The relationship between AMs and S. aureus enterotoxins has not been fully
explored. In vitro stimulation of human AMs with S. aureus enterotoxin A (SEA) induced IL-8
production in a dose-dependent manner (248). In another in vitro study, addition of
macrophages (AMs or peritoneal macrophages) reduced proliferation of SEA-activated T
cells via nitric oxide production (249). Although there is only a limited direct link between
AMs and S. aureus enterotoxins, indirect evidence exists that shows a relationship between
superantigens and conditions that deplete AMs. In particular, several reports from the 1980s
described development of toxic shock syndrome in patients with influenza and influenza-like
illness (250, 251). Furthermore, a recent study showed that the combination of cigarette
smoke exposure and S. aureus enterotoxin B (SEB) induced greater extent of pulmonary
inflammation than cigarette smoke or SEB alone (252). Based on these findings, we
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hypothesized that AMs play a critical role in the inflammatory responses triggered by S.
aureus enterotoxin inhalation.
Here we show that SEA was taken up by AMs upon inhalation and the enterotoxin
was found intracellularly and not on cell surface. Perhaps surprisingly, this binding was
independent of MHC II expression as SEA was similarly taken up by AMs of WT and MHC
II−⁄− mice. AMs in the murine lung express sialoadhesin, also known as CD169 on their
surface (229, 253). Thus, to study the role of AMs, CD169-diphteria toxin receptor (DTR)
mice were treated with diphtheria toxin (DT) and then exposed to SEA. The absence of AMs
was associated with increased CD25 expression on SEA-specific T cells but this effect was
only observed when lower concentrations of SEA were administered. Finally, SEA-exposed
CD169-DTR mice also showed a significantly greater cytokine secretion to blood compared
to WT mice. Thus, AMs may represent a defense mechanism against S. aureus
enterotoxins as their depletion may increase the severity of toxic shock or other S. aureus
enterotoxin-induced diseases.

Results

S. aureus enterotoxin preferentially binds to alveolar macrophages in MHC IIindependent manner
One of the crucial properties of S. aureus enterotoxins is their ability to rapidly induce
oligoclonal activation of T cells, which is accompanied by a massive inflammatory response
and cytokine storm (10). However, how SEA and other enterotoxins spread systemically,
especially from the airways as anterior nares are a common site of S. aureus colonies (11)
is not fully understood. In our previous studies we uncovered that SEA permeates into blood
immediately after inhalation and is found in the serum rather than bound to cells (183). The
ability to access circulatory system from airway mucosa is likely an important feature that
enables the toxin to spread systemically and activate T cells in lymphoid tissues within
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minutes of inhalation (30, 183). Furthermore, using a titration curve, the concentration of
SEA in serum after inhalation was estimated to be only a small fraction of the total amount
inhaled by a mouse (~ less than 1/35; unpublished data shown in Fig. 3-2). Intriguingly, in
another report using mass spectrometry, we showed that SEA could be recovered from BAL
fluid at 16 h after inhalation and the toxin preserved its biological activity (254). These
findings suggested that when SEA is inhaled, only a small portion enters the circulation
while the remainder may be retained in the lung mucosa or perhaps neutralized by various
defense mechanisms, such as defensins or phagocytosis.
Therefore, we sought to determine whether SEA binds to a certain cell population
within the pulmonary tissue. Lung was obtained from mice 8 h after SEA or vehicle
inhalation and examined by confocal microscopy for SEA using polyclonal anti-SEA
antibody. Only mice exposed to SEA displayed cells that were SEA+ (Fig. 5-1, A and B),
confirming the specificity of the antibody. Surprisingly, it was found that SEA was
preferentially bound to CD11c+CD169+ AMs (Fig. 5-1, A). In fact, a total of 87% of SEA+
cells were also positive for CD11c and 64% were both CD11c+ and CD169+ (Fig. 5-1, C). To
further define SEA binding to AMs, BAL fluid was obtained from mice 1, 4, or 24 h after SEA
inhalation and BAL AMs defined as CD45+CD11c+SIGLEC F+CD169+ (Fig. 5-1, D) were
stained for SEA. Importantly, no SEA was detected on the surface of AMs; however, there
was a significant increase in SEA presence intracellularly peaking at 4 h (Fig. 5-1, E and F).
Interestingly, there was no significant difference detected at 24 h after SEA (Fig. 5-1, F).
Similar results were obtained when AMs from lung tissue were analyzed (Fig. 5-2, A). In
contrast, lung dendritic cells showed increased SEA expression only at 24 h both on the
surface and intracellularly (Fig. 5-2, B).
S. aureus enterotoxins are known for their ability to directly bind to MHC II molecules
and crosslink them with specific Vβ chains of TCRs leading to a systemic inflammatory
response (10). However, AMs were reported to only express low levels of MHC II under
homeostatic conditions (226, 255) with MHC II expression increasing during an inflammatory
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response, particularly in the presence of IFNγ (256). Furthermore, AMs tend to be poor
antigen-presenters and may, in fact, inactivate T cells (257, 258). These findings suggested
that SEA binding to AMs could be MHC II-independent. To assess whether SEA binds to
AMs in MHC II-independent fashion, lung tissue was harvested from WT and MHC II−⁄− mice
8 h after SEA inhalation and analyzed by confocal microscopy. There was no difference in
the number of SEA+ cells between WT and MHC II−⁄− mice (Fig. 5-3, A and B). In addition,
SEA+ cells colocalized with CD11c marker with a similar frequency (Fig. 5-3, C). Finally, only
a small fraction of SEA+ cells colocalized with MHC II (Fig. 5-3, D) and in fact, we observed
CD11c+MHC II+ dendritic cells with no significant SEA binding (Fig. 5-3, A, white arrows).
Altogether, these results show for the first time that SEA binds to AMs in MHC IIindependent manner.

Depletion of alveolar macrophages is associated with increased T cell activation and
cytokine secretion
Next, we wanted to determine whether SEA binding to AMs impacts T cell activation
and cytokine production. We hypothesized that AMs sequester a large portion of the inhaled
toxin and neutralize it. Thus, AMs could play a protective role in SEA-induced inflammation.
To investigate the role of AMs in SEA-induced inflammatory response, we used CD169-DTR
mice to selectively deplete CD169+ macrophages after DT administration. Because AMs
express CD169 (Fig. 5-1), this technique can be used to study the role of AMs in pulmonary
responses (229). Thus, CD169-DTR mice and WT control were treated with DT 2 days prior
to SEA or vehicle inhalation. In order to avoid oversaturation of SEA dosage given to mice
(which could lead to masking of differences between WT and CD69-DTR mice), the SEA
dose was titrated (0.033, 0.1, 0.33, and 1 µg). Blood, lung and spleen were harvested 4 h
after SEA or vehicle (0 µg) inhalation. Depletion of CD169+ alveolar macrophages was
confirmed in the lung by gating on CD45+CD11c+SIGLEC F+CD169+ cells (Fig. 5-4, A). The
overall depletion of AMs was approximately 87% (Fig. 5-4, B). We first investigated the
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effect of CD169+ macrophage ablation on CD69 expression on SEA-specific Vβ3+ T cells in
the spleen. Interestingly, even with a low dose of SEA (0.033 µg), the percentage of CD69+
Vβ3+ T cells was 88.5% in WT mice and 89.8% in CD169-DTR mice, suggesting that a very
small amount of SEA is sufficient to induce CD69 expression on T cells (Fig. 5-4, C and D).
Thus, we concluded that CD69 expression might not be a sensitive marker to detect
differences in T cell activation. In contrast, CD25 expression on Vβ3+ T cells increased in a
dose-dependent manner (Fig. 5-4, F). Importantly, CD169-DTR mice showed significantly
greater percentage of CD25+ Vβ3+ T cells when 0.033 and 0.1 µg of SEA was administered
(Fig. 5-4, E and F). There was no significant effect on CD25 expression with the higher
doses of SEA (0.33 or 1 µg; Fig. 5-4, F). We also investigated the effect of AM ablation on
the bystander Vβ14+ T cells. There was no difference in the percentage of CD69+ and
CD25+ of Vβ14+ T cells with the exception of a significant increase in CD25+ Vβ14+ T cells in
CD169-DTR mice after a dose of 0.033 µg SEA (Fig. 5-4, D and F, right panels).
A hallmark of toxic shock syndrome as well as sepsis is a robust release of cytokines
into the bloodstream (36, 259). Therefore, we next investigated whether the depletion of
CD169+ macrophages affected cytokine secretion following SEA inhalation. Serum cytokine
concentrations were measured by a multiplex assay in DT pre-treated WT and CD169-DTR
mice 4 h after vehicle or SEA (0.033 or 0.1 µg) inhalation. There was no significant
difference in the levels of serum cytokine when vehicle control was administered. However,
following SEA inhalation, CD169-DTR mice had greater concentrations of serum G-CSF,
IFNγ, TNF, IL-2, IL-6, and also IL-10 compared to WT mice (Fig. 5-5). These findings show
that ablation of AMs is associated with increased expression of CD25 on SEA-specific Vβ3+
T cells and also increased secretion of cytokines into the circulation.

Discussion
Superantigens such as S. aureus enterotoxins are potent bacterial toxins that can
induce serious inflammatory responses and lethal shock (10). It has been estimated that

97

most strains of S. aureus are capable of producing superantigens (9, 260). However, S.
aureus is also an extremely common commensal that permanently colonizes about 20% of
all individuals (11). Thus, there is a disparity in understanding why S. aureus is so common
in asymptomatic individuals and simultaneously, it can trigger a life-threatening inflammatory
response. Although the mechanisms of how a commensal colonization can become
pathogenic are not clear (260), it has been well established that patients who have
colonization of anterior nares with S. aureus and particularly methicillin resistant S. aureus
(MRSA) are more susceptible to hospital-acquired S. aureus infections (101-103). This
suggests that various defense mechanisms must be in place to prevent the spread of the
bacteria and limit the effects of the virulence factors; however, these mechanisms may be
impaired in immunocompromised individuals in hospital settings.
Indeed, the immune system possesses several strategies to counteract the harmful
effects of superantigens. First, It has been hypothesized that the production of antibodies
against superantigens is protective and the lack of antibodies may a predisposing factor for
the development of S. aureus infections and toxic shock syndrome (261-263). In particular,
women with toxic shock syndrome had lower antibody titers to TSST-1 compared to healthy
women with no prior history of toxic shock syndrome (262). Similarly, immunotherapy using
antibodies specific to superantigens was found to be protective in animal models (264-266).
In addition to antibodies, it has been shown that lactoferrin, an iron-binding glycoprotein
located predominantly in mucosal secretions (267), can attenuate the inflammatory
responses triggered by S. aureus enterotoxins (254, 268). Here we show that AMs may
represent a key cellular defense mechanism that can reduce the effects of S. aureus
enterotoxin-induced inflammation.
When staining for SEA in the lung tissue, we found that AMs preferentially bound
SEA after inhalation and internalized it (Fig. 5-1). Interestingly, the intracellular presence of
SEA in AMs increased in the first several hours but was not significantly different at 24 h
(Fig. 5-1, F and 5-2, A). In addition, dendritic cells, which were hypothesized to bind a
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significant amount of SEA due to their high MHC II expression, showed upregulation of SEA
expression on surface and intracellularly only at 24 h after inhalation (Fig 5-2, B). Based on
these findings, we postulate that the numerous and highly phagocytic AMs ingest SEA and
thus reduce the ability of dendritic cells either in the lung mucosa or in other tissues to take
up the antigen and present it. In fact, AMs have been shown to maintain the lung
homeostasis by suppressing dendritic cell function (269, 270). The later presence of SEA on
pulmonary dendritic cells could perhaps be due to antigen transfer from AMs to dendritic
cells (271).
Superantigens, such as S. aureus enterotoxins, are known for their ability to bind to
MHC II directly without antigen processing, which results in rapid oligoclonal activation of T
cells and a cytokine storm (10). In addition, compared to SEB, SEA was found to have a
greater affinity for MHC II due to its ability to not only bind the α chain but also the β chain of
MHC II with a zinc-dependent binding site, which enabled SEA to stay on cell surface for at
least 40 h (26). Interestingly, we found that the binding of SEA to AMs was independent of
MHC II expression (Fig. 5-3). Binding of S. aureus enterotoxins to molecules other than
MHC II have been previously reported. In particular, the costimulatory molecule CD28 and
its ligand CD86 are crucial binding sites that enhance the severity of the inflammatory
response triggered by S. aureus enterotoxin (27-29). Other binding sites for S. aureus
enterotoxins have been reported, including MHC I (272), digalactosylceramide on kidney
proximal tubular cells (273) and Gp130 receptor on adipocytes (274). These studies show
that S. aureus enterotoxins may bind to several different molecules. Thus, it will be
important to determine the identity of the binding site of SEA on AMs as well as the
processing of the enterotoxin by these phagocytes.
Previous studies showed that following intranasal S. aureus enterotoxin exposure,
mice experience a systemic oligoclonal T cell activation and cytokine release to blood (23,
34, 183, 275). To examine the role of AMs in the SEA-induced inflammatory response, WT
and CD169-DTR mice were treated with DT and 2 days later, they were exposed to vehicle
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or SEA. There was no difference in the expression of activation markers CD25 or CD69 on
SEA-specific Vβ3+ T cells as well as no significant change in serum cytokines when mice
were administered vehicle control (Fig. 5-4 and 5-5). However, CD169-DTR exposed to SEA
showed a significantly greater CD25 expression compared to WT mice (Fig. 5-4, F). This
was only observed when lower amounts of SEA were given, suggesting that the higher
doses of SEA saturate the level of T cell activation. Indeed, even 0.033 µg of SEA activated
almost 90% of SEA-specific Vβ3+ T cells in the spleen (Fig. 5-4, F). These findings
emphasize the potency of SEA, which even in a small amount is sufficient to trigger a
significant response. Furthermore, we examined the concentrations of serum cytokines
commonly associated with toxic shock syndrome and sepsis, in particular, TNF, IFNγ, IL-2,
and IL-6 (36, 75, 259). IL-10 and G-CSF were also analyzed. G-CSF, a growth factor that
mobilizes neutrophils into circulation during acute inflammation (128), was previously found
elevated in patients with bacterial infection (276, 277) while the anti-inflammatory cytokine
IL-10 can be released in septic patients in attempt to counteract the hyper-inflammatory
response (259). Importantly, SEA-exposed CD169-DTR mice had increased secretion of
pro-inflammatory cytokines TNF, IFNγ, IL-2, IL-6 as well as G-CSF demonstrating that AM
ablation is associated with enhanced inflammatory response following SEA inhalation (Fig.
5-5). Interestingly, the concentration of anti-inflammatory IL-10 was also elevated in CD169DTR mice (Fig. 5-5). This is consistent with our previous study showing that SEA
simultaneously induced the expression of both pro-inflammatory cytokines IL-2, TNF, and
IFNγ and anti-inflammatory IL-10 in SEA-specific Vβ3+ T cells (183). Thus, depletion of AMs
was correlated with an overall enhancement of the SEA-induced immune response.
Finally, CD169 is expressed not only on AMs but also other macrophages, including
marginal zone macrophages in the spleen and subcapsular sinus macrophages in the LNs
(278, 279). Therefore, depletion of macrophage subsets other than AMs could also
contribute to the enhanced inflammatory response observed in CD169-DTR mice. Similarly,
it is also possible that DT injection and the subsequent cell apoptosis could play a role in the
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increased inflammatory response in CD169-DTR mice. Therefore, further studies will be
necessary to confirm the causal relationship between AMs and S. aureus enterotoxininduced systemic inflammatory response.
In conclusion, here we show that AMs preferentially bind S. aureus enterotoxin in
MHC II-independent manner and internalize it. Furthermore, AM ablation in CD169-DTR
mice was associated with increased activation of SEA-specific Vβ3+ T cells and enhanced
secretion of cytokines into circulation. These findings could explain the development of toxic
shock syndrome in patients with influenza infection (250, 251) as well as the increased risk
of sepsis and ARDS in chronic alcohol users and smokers, respectively (243-246). Thus,
dysfunction or depletion of AMs may be a critical risk factor for the development of S. aureus
enterotoxin-induced inflammatory diseases.
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FIGURE 5-1: SEA preferentially binds to AMs upon inhalation. A) Representative
confocal microscopy images of lung tissue 8 h after SEA or vehicle inhalation. Lung sections
were stained with anti-SEA (green), anti-CD11c (red), and anti-CD169 (blue). Magnified
images of the areas marked by white squares in the overlay panels are shown on the left.
Size bar = 80 µm. 4 independent experiments with total n=5 per group. B) Number of SEA+
cells per field. Three images from each mouse were quantified (4 independent experiments
with n=5 per group) by Imaris (Bitplane). C) Percentage of CD11c+CD169+ and
CD11c+CD169− cells in all SEA+ cells detected by confocal microscopy 8 h after SEA
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inhalation. SEA+ cells were colocalized with CD11c+ cells and SEA+CD11c+ cells were
further colocalized with CD169 by Imaris. The average percentage shown in the pie chart
was calculated from 3 images per mouse (3 independent experiments with total n=4). D)
Gating strategy to identify AMs in the BAL fluid by flow cytometry. BAL fluid was obtained 1,
4, or 24 h after SEA inhalation or from vehicle control (1 or 4 h) and AMs were identified as
live CD45+CD11c+SIGLEC F+CD169+ cells. E) Representative histograms showing SEA
expression on surface and intracellularly in BAL fluid AMs. F) Relative median fluorescent
intensity (MFI) of SEA on surface and intracellularly in BAL fluid AMs 1, 4, or 24 h after SEA
inhalation. MFI values are relative to the vehicle control (set as 1). Three independent
experiments with total n=7 per group. Data are represented as mean ± SEM. Unpaired t test
(B) or one-way ANOVA with Dunnett’s test (F); *p<0.05, ***p<0.001.

FIGURE 5-2: SEA presence in lung AMs and DCs. Lung tissue was harvested 1, 4, or 24
h after SEA inhalation or from vehicle control (1 or 4 h). AMs were identified as live
CD45+CD11c+SIGLEC F+CD169+ cells and DCs as live CD45+CD11c+SIGLEC F−MHC II+.
A) Relative median fluorescent intensity (MFI) of SEA on surface and intracellularly in lung
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AMs 1, 4, or 24 h after SEA inhalation. B) Relative MFI of SEA on surface and intracellularly
in lung DCs 1, 4, or 24 h after SEA inhalation. MFI values are relative to the vehicle control
(set as 1). Two independent experiments with total n=4 per group. Data are represented as
mean ± SEM. One-way ANOVA with Dunnett’s test was used; *p<0.05, ** p<0.01,
***p<0.001.

FIGURE 5-3: SEA binding to AMs is MHC II-independent. A) Representative confocal
microscopy images comparing SEA binding in WT and MHC II−⁄− mice 8 h after SEA
inhalation. Lung sections were stained with anti-SEA (green), anti-CD11c (red), and antiMHC II (blue). Magnified images of the areas marked by white squares in the overlay panels
are shown on the left. White arrows in the magnified panel (WT) point to dendritic cells
(CD11c+MHC II+). Size bar = 80 µm. Three independent experiments with total n=5 per
group. B) Number of SEA+ cells per field. Three images from each mouse were quantified (3
independent experiments with n=5 per group) by Imaris (Bitplane). C) Percentage of CD11c+
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cells in all SEA+ cells detected by confocal microscopy 8 h after SEA inhalation. SEA+ cells
in WT and MHC II−⁄− mice were colocalized with CD11c+ cells by Imaris (3 images per
mouse; 3 independent experiments with n=5 per group). D) Percentage of MHC II+ cells in
all SEA+ cells detected by confocal microscopy 8 h after SEA inhalation. SEA+ cells in WT
mice were colocalized with MHC II+ cells by Imaris (3 images per mouse; 3 independent
experiments with n=5 per group). Data are represented as mean ± SEM. Unpaired t test.

FIGURE 5-4: Depletion of CD169+ cells leads to increased expression of CD25 on
SEA-specific Vβ3+ T cells. WT and CD169-DTR mice received DT 2 days prior to SEA or
vehicle inhalation. Lung and spleen were removed 4 h after vehicle (0 µg) or SEA (0.033,
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0.1, 0.33 or 1 µg) inhalation. A) and B) Representative flow cytometry plots (A) and scatter
dot plot (B) showing depletion of AMs in lung (gated as live CD45+CD11c+SIGLEC
F+CD169+ cells) in CD169-DTR mice compared to WT mice. The percentage of AMs is
relative to all live cells. C) Representative histogram of CD69 expression in live
CD45+CD3+Vβ3+ cells in WT (black) and CD169-DTR (red) mice 4 h after 0.033 µg SEA
inhalation. Gray = isotype control. D) Percentage of CD69+ cells in Vβ3+ (left) and Vβ14+
(right) T cells 4 h after 0, 0.033, 0.1, 0.33 or 1 µg of SEA inhalation. E) Representative
histogram of CD25 expression in live CD45+CD3+Vβ3+ cells in WT (black) and CD169-DTR
(red) mice 4 h after 0.033 µg SEA inhalation. Gray = isotype control. F) Percentage of
CD25+ cells in Vβ3+ (left) and Vβ14+ (right) T cells 4 h after 0, 0.033, 0.1, 0.33 or 1 µg of
SEA inhalation. The data were compiled from 3 independent experiments with total n=5-6
per group. Two-way ANOVA with Sidak’s test; *p<0.05, **p<0.01, ***p<0.001.

FIGURE 5-5: Depletion of CD169+ cells increases the concentration of serum
cytokines after SEA inhalation. Serum was obtained from tail blood 4 h after vehicle (0 µg)
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or SEA (0.033 or 0.1 µg) inhalation. The concentrations of different cytokines were
measured by a bead-based multiplex assay (EMD Millipore). The data were compiled from 3
independent experiments with total n=6 per group. Two-way ANOVA with Sidak’s test;
*p<0.05, **p<0.01, ***p<0.001.

107

Chapter 6: Conclusions and Future Directions

Together with previous reports (30, 34, 39, 106, 254), these studies demonstrated
the intricate pathways employed in S. aureus enterotoxin-induced inflammation and the key
findings are shown in Fig. 6.1 and Fig. 6.2. Fig. 6.1 depicts the early inflammatory
responses following SEA inhalation; in particular, how SEA spreads systemically from the
airways and how the activated adaptive immunity triggers the recruitment of innate immune
cells to blood, LNs and lung. Fig. 6.2 shows the pulmonary responses leading to lung injury
2 days after SEA inhalation. Although these findings uncovered various mechanisms in S.
aureus enterotoxin-induced inflammation and potentially also in SIRS/sepsis and ALI/ARDS,
there are several remaining questions.
Firstly, it will be important to further investigate the role of innate immune cells,
particularly neutrophils and monocytes, in S. aureus enterotoxin inflammatory response.
Both chapter 3 and chapter 4 demonstrated that neutrophils and inflammatory monocytes
are recruited to blood, lymphoid tissues and lung (183, 275). However, it is not currently
clear whether the recruitment and activation of innate cells contributes to the severity of the
response or actual tissue injury. Neutrophils and monocytes are considered the first line of
immune defense in acute inflammatory response and their non-specific products, such as
reactive oxygen species and proteolytic enzymes, are thought to be responsible for the
host’s tissue injury (2-4). Thus, it will be important to determine to what extent the innate
immune cells affect S. aureus enterotoxin-induced inflammatory response (e.g. in the T cell
zone of the LNs following their recruitment) and cell damage (e.g. in the lung 2 days after
inhalation).
Secondly, the role of AMs in systemic inflammation following S. aureus enterotoxin
exposure warrants further studies. The findings of chapter 5 unraveled an important
relationship between AMs, SEA and the subsequent systemic inflammatory response. In
particular, depletion of AMs was associated with increased inflammation following SEA
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inhalation. However, it is not known which receptor SEA binds on AMs to and how the
macrophages process the enterotoxin intracellularly. Furthermore, usage of alternative AM
ablation models (e.g. intrathoracic administration of DT in CD169-DTR mice) will establish a
more direct link between AMs and S. aureus enterotoxins. These future studies may help to
determine at-risk patients who may be more susceptible to S. aureus enterotoxin exposure.
Thirdly, chapter 4 uncovered that CD54 is a critical player in SEA-evoked lung injury
and blocking CD54 many hours after the exposure significantly reduced inflammation and
tissue damage (275). Although it was shown that therapeutic CD54 blockade significantly
reduces T cell recruitment to lung, it is also possible that the direct engagement of CD54
with its binding partners (e.g. CD11a) plays a vital role in triggering damage to endothelial
cells (196, 280). Furthermore, it will be interesting to explore whether such pathways are
dependent on the presence of an antigen (i.e. SEA) or whether they can occur
independently of TCR binding.
Finally, it will be critical to further establish the causal relationship between
superantigens and the pathogenesis of SIRS/sepsis and ALI/ARDS in humans. Prior studies
have preferentially focused on studying Gram-negative bacteria and particularly the effects
of LPS on eliciting immune response and cell injury. However, a recent study showed that
47% of patients in intensive care units with a serious infection were infected with Grampositive bacteria and S. aureus was present in 20% of cases (87). Thus, superantigens may
represent a crucial trigger of SIRS/sepsis and ALI/ARDS. There is currently no standard
test used to detect superantigens in patients. Ideally, such test would detect superantigen
proteins in anterior nares, blood or BAL fluid of patients who are at risk or presenting with
symptoms of SIRS or ALI. Detection of superantigen proteins would be preferable to
analyzing gene expression in S. aureus strains that were extracted from patients as
superantigens are not necessarily transcribed and translated continuously (10).
Alternatively, a functional immunoassay could be used that would detect clonal T cell
activation or expansion or the downstream effects, such as IL-2 production in a co-culture
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assay of naïve T cells with BAL fluid or serum obtained from patients (183, 254). This would
also demonstrate that the immune system is responding as some individuals may have
neutralizing antibodies to superantigens.
In conclusion, S. aureus enterotoxins and other superantigens are potent but
currently underrated virulence factors. Unlike LPS and other pathogen associated molecular
patterns (PAMPs), they trigger a robust immune response through oligoclonal activation of T
cells rather than pattern recognition receptors (PRRs). T cells then orchestrate other arms of
the immune system, which results in systemic inflammatory response and organ damage.
Thus, S. aureus enterotoxins and other superantigens trigger unique pathways that merit
further investigation, especially in the field of SIRS/sepsis and ALI/ARDS. Understanding
these mechanisms will enhance our knowledge of these devastating diseases and may lead
to discovery of novel therapeutic targets.
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FIGURE 6.1: Summary of systemic inflammatory responses following SEA inhalation.
SEA (marked as ✦) enters the airways through the nasal cavity and reaches the lung
mucosa and individual alveoli. SEA gets trapped inside alveolar macrophages (AMs) which
likely reduces the amount of the enterotoxin that gets into the circulation and the subsequent
inflammatory response (Chapter 5; unpublished). SEA can be found in the blood within
minutes of inhalation and it disseminates systemically. In LNs and spleen, SEA binds
dendritic cells (DCs), particularly migratory DCs, and activates SEA-specific T cells (e.g.
Vβ3+) inducing a robust cytokine and chemokine release (marked as ). More specifically,
TNF and CD28 signaling play unique but complementary roles in triggering systemic
migration of the innate immune cells (neutrophils and inflammatory monocytes) from the
bone marrow and likely also the marginated pool. The chemotactic gradient recruits the
circulating neutrophils and monocytes into spleen and LNs, particularly the T cell zone
(Chapter 3; (183)). Because SEA-specific T cells are also found in the lung under
homeostatic conditions, they also become activated and secrete cytokines and chemokines,
including CXCL1 and IL-12p40 (Chapter 4; (275)). Furthermore, the cytokine IL-2 plays a
role in triggering IL-17 release from γδ T cells aiding the recruitment of neutrophils ((30); A.
Ménoret, unpublished work). The pulmonary immune responses and/or the circulating
cytokines induce activation of pulmonary endothelial cells, including pSTAT1 and MHC II
upregulation and changes in gene transcription (Chapter 4; (275)).
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FIGURE 6.2: Summary of pulmonary inflammatory responses following SEA
inhalation. Two days after SEA inhalation, the population of SEA-specific T cells (e.g. Vβ3+)
becomes significantly expanded within the lymphoid tissues. SEA-specific T cells and
particularly CD8+ T cells then accumulate in the lung (process dependent on CD4+ T cell

113

help) and induce production of cytokines and chemokines, including IFNγ, IL-6, CXCL1 and
CCL2 ((39) and also Chapter 4; (275)). These factors induce the recruitment of NK cells,
neutrophils and monocytes to the lung ((30) and also Chapter 4; (275)). The population of
pulmonary endothelial cells downregulates the expression of eNOS and upregulates Fas
and CD54 (marked as | ). These cumulative inflammatory responses are largely dependent
on CD54 expression and trigger injury to epithelial and endothelial cells (marked as grey
cells with injury markers shown as ✷) and increased lung permeability, further propagating
the inflammation within the tissue (Chapter 4; (275)).
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